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ABSTRACT 
The myocardium of patients with coronary artery disease (CAD) often is a mixture 
of ischaemic but viable tissue and irreversibly injured scar tissue. The viable tissue 
has capability of functional recovery after restoration of blood flow and the 
assessment of myocardial viability is important in identifying patients who will most 
likely benefit from revascularisation. Angiogenesis is an essential part of the healing 
process after ischaemic myocardial injury aiming at restoration of intact tissue 
capillary network. Measurement of myocardial blood flow by positron emission 
tomography (PET) and [15O]water is widely used in the evaluation of CAD, but its 
value in the assessment of myocardial viability is incompletely understood. 
[68Ga]NODAGA-RGD is a novel PET tracer binding to αvβ3 integrin that plays a 
central role in angiogenesis and therefore, may enable imaging of angiogenic 
activity. 
The purpose of this thesis was to evaluate [15O]water and [68Ga]NODAGA-RGD 
for the assessment of myocardial viability and ischaemic myocardial injury by PET 
in experimental models. We used pig models of surgically or percutaneously induced 
coronary stenosis and human cell based in vitro model of angiogenesis. In the first 
substudy, we found that resting myocardial blood flow (MBF), perfusable tissue 
fraction (PTF) and perfusable tissue index (PTI) by [15O]water PET detected 
myocardial viability with good accuracy in pig models of ischaemic heart failure and 
myocardial ischaemia. In the second substudy, we found that [68Ga]NODAGA-RGD 
demonstrated increased myocardial αvβ3 integrin expression in the ischaemic 
myocardium that was localised in the irreversibly injured myocardium. In the third 
substudy, we found that the uptake of [68Ga]NODAGA-RGD was proportional to 
angiogenic activity in an in vitro angiogenesis tissue model. 
In conclusion, these experimental studies indicate that resting MBF, PTF and 
PTI by [15O]water PET are useful indexes of myocardial viability in chronic CAD. 
[68Ga]NODAGA-RGD PET may be useful for the identification of αvβ3 integrin 
activation associated with recent ischaemic myocardial injury. This tracer reflects 
angiogenetic activity in vitro, but its specificity for angiogenesis in vivo remains 
uncertain. 
KEYWORDS: Coronary artery disease, myocardial infarction, myocardial viability, 
angiogenesis, positron emission tomography  
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TIIVISTELMÄ 
Sepelvaltimotautipotilaiden sydänlihas koostuu usein iskeemisestä, mutta elin-
kykyisestä ja peruuttamattomasti vaurioituneesta kudoksesta. Elinkykyisen 
sydänlihaksen toiminta voi palautua normaaliksi verenkierron palauttamisen jälkeen, 
ja elinkykyisyyden arviointi on tärkeää verenkierron palauttamisesta hyötyvien 
potilaiden tunnistamisessa. Uudisverisuonitus eli angiogeneesi, jonka tarkoitus on 
palauttaa kudokseen toimiva hiussuoniverkosto, on tärkeä osa iskeemisen vaurion 
jälkeistä paranemista. Sydänlihaksen verenvirtauksen mittaaminen positroni-
emissiotomografialla (PET) käyttäen merkkiaineena [15O]vettä on paljon käytetty 
menetelmä sydäntaudin arvioinnissa, mutta sen soveltuvuutta sydänlihaksen 
elinkykyisyyden arviointiin ei tiedetä. [68Ga]NODAGA-RGD on uusi angiogeneesiä 
säätelevään αvβ3 integriiniin sitoutuva merkkiaine jonka avulla voitaisi mahdollisesti 
kuvantaa sydänlihaksen angiogeenistä aktiivisuutta. 
Väitöskirjatyön tarkoituksena oli arvioida [15O]vesi ja [68Ga]NODAGA-RGD 
PET:n käyttökelpoisuutta sydänlihaksen elinkykyisyyden ja iskeemisen sydän-
lihasvaurion tunnistamisessa kokeellisilla malleilla. Käytimme sikoja, joille oli 
aiheutettu sepelvaltimotukos kirurgisesti tai katetrisaatiolla, sekä ihmissolupohjaista 
kokeellista angiogeneesin kudosmallia. Ensimmäisessä osatyössä havaitsimme, että 
[15O]vesi PET:n tehokkuus elinkykyisyyden havaitsemisessa iskeemisen sydämen 
vajaatoiminnan ja sydänlihasiskemian sikamalleissa oli hyvä. Toisessa osatyössä 
havaitsimme, että [68Ga]NODAGA-RGD:llä voitiin havaita lisääntynyt αvβ3 
integriiniaktivaatio, joka sijaitsi peruuttamattomasti vaurioituneessa sydänlihak-
sessa. Kolmannessa osatyössä havaitsimme, että [68Ga]NODAGA-RGD:n kertymä 
oli verrannollinen angiogeneesiaktivaatioon kokeellisessa angiogeneesin kudomal-
lissa.  
Yhteenvetona voidaan todeta, että [15O]vesi PET on käyttökelpoinen sydän-
lihaksen elinkykyisyyden arvioinnissa kroonisessa sepelvaltimotaudissa. 
[68Ga]NODAGA-RGD PET voi olla käyttökelpoinen tuoreeseen sydänlihasvaurioon 
liittyvän αvβ3 integriiniaktivaation kuvantamisessa. Tämä merkkiaine kuvastaa 
angiogeenistä aktivaatiota kokeellisesti, mutta sen tarkkuus elävässä elimistössä on 
epäselvää. 
AVAINSANAT: Sepelvaltimotauti, sydäninfarkti, sydänlihaksen elinkykyisyys, 
uudisverisuonitus, positroniemissiotomografia  
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Abbreviations 
ACE Angiotensin-converting enzyme 
AT Angiotensin 
AT1R Angiotensin II subtype 1 receptor 
ATF Anatomical tissue fraction 
ATP Adenosine triphosphate 
AUC Area under the curve 
CAD Coronary artery disease 
CMR Cardiac magnetic resonance 
CT Computed tomography 
cTN Cardiac troponin 
DAMP Danger-associated molecular pattern 
ECG Electrocardiogram 
ECM Extracellular matrix 
EDWT End diastolic wall thickness 
FDG Fluorodeoxyglucose 
FGF Fibroblast growth factor 
GLUT Glucose transporter 
GMP Good manufacturing practice 
hASC Human adipose stromal cells 
HF Heart failure 
HIF Hypoxia-inducible factor 
HMGB1 High mobility group box 1 
HSP Heat shock protein 
HUVEC Human umbilical vein endothelial cells 
IAP Inhibitor of apoptosis 
IHD Ischaemic heart disease 
IL Interleukin 
LAD Left anterior descending artery 
LV Left ventricle 
MI Myocardial infarction 
MBF Myocardial blood flow 
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MPI Myocardial perfusion imaging 
MRI Magnetic resonance imaging 
PBS Phosphate-buffered saline 
PET Positron emission tomography 
PSL Photostimulated luminesence 
PTF Perfusable tissue fraction 
PTI Perfusable tissue index 
RAAS Renin-angiotensin-aldosterone system 
RGD Arginine-glycine-aspartic acid 
ROC Receiver operating characteristics 
ROI Region of interest 
ROS Reactive oxygen species 
SMA Smooth muscle actin 
SPECT Single photon emission computed tomography 
SUV Standardised uptake value 
TGF Transforming growth factor 
TLR Toll-like receptor 
TNF Tumor necrosis factor 
TTC 2,3,5-triphenyltetrazolium chloride 
VEGF Vascular endothelial growth factor 
VOI Volume of interest 
vWF von Willebrand factor 
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1 Introduction 
Ischaemic heart disease (IHD) is the leading global cause of death (Moran et al., 
2014). It is caused by atherosclerosis of the coronary arteries and can also be called 
coronary artery disease (CAD). The atherosclerotic plaques start to develop early 
and slowly progress to narrow the artery lumen, reduce the myocardial blood flow 
(MBF) and cause myocardial ischemia. The myocardium of patients with CAD and 
left ventricle (LV) dysfunction often contains a mixture of ischemic, but viable and 
irreversibly injured, non-viable tissue. The viable tissue still has capability of 
regaining contractile function after the restoration of blood flow, whereas non-viable 
tissue does not benefit from revascularisation (Bax & Delgado, 2015). Myocardial 
perfusion imaging (MPI) with positron emission tomography (PET) using [15O]water 
is a standard tool in assessing MBF in patients with CAD but its feasibility in the 
assessment of myocardial viability is yet to be determined.  
The most dramatic manifestation of IHD is myocardial infarction (MI), which 
usually is a result of a rupture of an atherosclerotic plaque and subsequent thrombosis 
within the artery lumen. MI is defined as acute myocyte necrosis following 
prolonged ischaemia (Thygesen et al., 2019). MI is followed by a three-phase healing 
process which includes inflammation, angiogenesis, fibroblast proliferation and 
eventually scar formation (Frangogiannis, 2006). Poor infarct healing can cause 
alterations in the LV involving both the infarcted and noninfarcted regions in a 
process defined as adverse LV remodelling, which can eventually lead to progressive 
LV dysfunction and development of chronic heart failure (HF). Despite 
developments in therapy, the prognosis of HF is generally poor as half of the patients 
with HF die within five years of the initial diagnosis (Mcmurray & Pfeffer, 2004). 
Angiogenesis, that is induced in the myocardial tissue after an ischaemic insult to 
preserve enough blood flow in the affected area, is an integral part of infarct healing. 
Integrin αvβ3 is one of the most important integrins that regulate angiogenesis. Its 
expression is generally low in endothelial cells but elevated during angiogenesis. 
The detection of myocardial αvβ3 integrin expression with PET using radiolabelled 
arginine-glycine-aspartic acid (RGD) peptides is a potential tool in monitoring LV 
remodelling after MI (Sherif et al., 2012).  
Maria Grönman 
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In order to guide therapy and improve prognosis, identifying the patients with 
CAD and LV dysfuction that will most likely benefit from revascularisation or are 
at high risk for developing HF after MI is important.  
In the studies of this thesis, MPI with [15O]water PET was studied for the 
assessment of myocardial viability after experimental MI. Also, the feasibility of a 
novel angiogenesis targeting PET tracer [68Ga]NODAGA-RGD was evaluated for 
the detection of integrin expression in a pig model of myocardial ischaemia. Finally, 
the uptake of [68Ga]NODAGA-RGD was studied  in comparison to the amount of 
angiogenesis in an in vitro angiogenesis tissue model.
 13 
2 Review of the Literature 
2.1 Ischaemic heart disease 
2.1.1 Coronary artery disease 
The modern sedentary lifestyle in combination with high energy diet has led to 
high rate of ischaemic heart disease (IHD). The incidence of IHD has declined in 
the high-income countries during the last decades due to improved prevention and 
treatment but it, however, still remains the leading cause of death worldwide as the 
mortality is even increasing in low- and middle-income regions (Moran et al., 
2014; Nowbar et al., 2019). Ischaemic heart disease, also called coronary artery 
disease (CAD), is caused by atherosclerosis in the epicardial coronary arteries, 
which eventually leads to narrowing of the artery lumen and myocardial ischaemia, 
i.e. decrease in the blood supply to myocardium. The main features of 
atherosclerosis are lipid accumulation into the intima with simultaneous 
inflammation. Atherosclerotic plaques start to develop already during childhood 
by formation of fatty streaks in the intima layer of the arteries (Stary et al., 1994). 
The disease progresses slowly over the decades and does not represent symptoms 
until at later stages of life. The fatty streaks evolve into atheromas, which might 
eventually grow to narrow the lumen of the artery leading to reduced blood flow 
and ischaemia, or rupture causing myocardial infarction (MI) (Gibson et al., 2018; 
Libby, 2002). CAD may present various symptoms depending on the severity of 
the stenosis. The first symptoms include shortness of breath and chest pain also 
called angina pectoris. These usually appear during exercise when the oxygen 
demand of the heart is increased and are absent at rest. In some cases, the first 
symptom of CAD might, however, be acute MI (Knuuti et al., 2020).  
2.1.2 Myocardial ischaemia and infarction 
Reduced blood flow in the myocardium, most commonly due to atherosclerosis, 
results in an imbalance between the oxygen demand and supply and myocardium 
becomes ischaemic. Myocardium can shift between different substrates to produce 
energy in the form of adenosine triphosphate (ATP). In normal conditions ATP is 
Maria Grönman 
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mainly produced by oxidising free fatty acids and to a lesser extent by metabolising 
carbohydrates and ketone bodies. However, for example during exercise or fasting, 
when lactate or ketone bodies become abundantly available myocardium utilises 
them in the energy production. In an ischaemic myocardium glycolysis is stimulated 
by hypoxia-inducible factor (HIF) 1α and the energy is shifted towards glucose 
metabolism, which has better oxygen efficiency in the ATP production. (Kolwicz et 
al., 2013) The fate of the myocytes during ischaemia depends on the duration and 
degree of the ischaemia. Ischemia leads to impaired function of ion channels in the 
cell membrane and to myocyte oedema. Myocytes lose their contractile function, 
which may remain for days after the restoration of the blood flow. (McDiarmid et 
al., 2017; Stanley et al., 2005)  
MI is pathologically defined as cardiomyocyte death caused by prolonged 
ischaemia (Thygesen et al., 2019). The first ultrastructural changes, such as 
diminished cellular glycogen, relaxed myofibrils, sarcolemmal disruption and 
mitochondrial abnormalities, occur already in 10-15 minutes after the onset of 
ischaemia (Thygesen et al., 2019). The injury caused by short period of ischaemia 
usually is reversible and the myocytes might survive if the blood flow is restored. 
Longer periods of ischaemia lead to irreversible injury and myocytes start to die 
by necrosis (Reimer et al., 1977). Ischaemia-induced necrosis is characterised by 
swelling of the cells, sarcolemmal disruption, mitochondrial calcification and 
inflammation (Majno & Joris, 1995; Reimer et al., 1977). The necrosis occurs first 
in the subendocardium and progresses transmurally (Reimer et al., 1977). It can, 
however, take several hours before complete cell death occurs depending on the 
amount of collateral flow, individual needs in myocardial oxygen consumption and 
recurring episodes of occlusion and reperfusion that lead to preconditioning of the 
heart (Thygesen et al., 2019). Diagnosis of MI is based on the rise and/or fall of 
circulating cardiac troponin (cTn) values, combined with clinical symptoms of 
ischaemia, changes in electrocardiography (ECG) or imaging evidence of coronary 
thrombus or ischaemia. (McDiarmid et al., 2017; Thygesen et al., 2019) 
2.1.3 Healing after myocardial infarction 
A repair process is initiated after the MI aiming to clear the infarct area from tissue 
debris and eventually replace the damaged myocardium with a scar. The infarct 
healing process is generally divided into three phases: the inflammatory phase, 
proliferative phase, and maturation phase. The rapid inflammatory response aims to 
clear the infarct area from cellular and extracellular matrix (ECM) debris during the 
first 4 days after the MI. The wound healing and neovascularisation begin as the 
proliferative phase takes place for the next couple of weeks. Finally, a scar is formed 
during the maturation phase, which takes approximately 2 months in large mammals. 
Review of the Literature 
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The main events and cell types of infarct healing process are summarised in Figure 
1 (Dobaczewski et al., 2010; Liehn et al., 2011). 
2.1.3.1 Inflammatory phase 
Injured cardiomyocytes activate the innate immune pathways and inflammatory 
response by releasing endogenous ligands called danger-associated molecular 
patterns (DAMPs). The released “danger signals” include high mobility group box 1 
protein (HMGB1), heat shock proteins (HSPs), ATP, hyaluronan and fibronectin, 
among others (Andrassy et al., 2008; Arslan et al., 2011; Gupta et al., 2012). DAMPs 
activate the proinflammatory cascade mainly via toll-like receptors (TLRs) and 
interleukin-1 (IL-1) receptors in several cell types such as cardiomyocytes, 
endothelial cells, resident cardiac fibroblasts and mast cells, and newly recruited 
leukocytes and platelets. Downstream pathways, especially nuclear factor-kappa B 
(NF-κB), activated by TLRs and reactive oxygen species (ROS), enhance the 
expression of proinflammatory cytokines, for example tumor necrosis factor (TNF), 
IL-1β, IL-6 and IL-18, chemokines and cell adhesion molecules. (Arslan et al., 2011; 
Frangogiannis, 2014; Park et al., 2004) 
Induced expression of chemokines attracts neutrophils, which are the first 
inflammatory cells to infiltrate the infarcted myocardium. Neutrophils participate in 
cleaning the area from dead tissue debris and increase the immune response. In 
addition to neutrophils, cytotoxic T-lymphocytes are early players in the infarction 
site. Monocytes are recruited to the infarction site in two phases. The early 
recruitment of monocytes shortly after the neutrophils consists of proinflammatory, 
phagocytic monocytes and M1 macrophages, whereas the monocytes and M2 
macrophages arriving later have anti-inflammatory effects (Nahrendorf et al., 2007; 
Yan et al., 2013).   
2.1.3.2 Proliferative phase 
When the first days after the infarction are characterised by strong proinflammatory 
response, the proliferative phase begins with the suppression of the inflammation, 
which is essential for the reparative actions to begin.  Neutrophils have a short life 
cycle and when at late stage and apoptotic, they start to release mediators, such as 
lipoxins, resolvins, annexin A1 and lactoferrin that inhibit neutrophil transmigration 
and promote apoptosis and phagocytic uptake of neutrophils by macrophages 
(Soehnlein & Lindbom, 2010). The neutrophils polarise macrophages towards anti-
inflammatory and reparative M2 phenotype (Horckmans et al., 2017) that releases 
anti-inflammatory, pro-fibrotic and angiogenic mediators, such as IL-10, members 
of transforming growth factor (TGF)-β family and vascular endothelial growth factor 
Maria Grönman 
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(VEGF) (Soehnlein & Lindbom, 2010). Also, dendritic cells and regulatory T-
lymphocytes infiltrate the infarcted myocardium and contribute to the suppression 
of inflammation. Some members of the chemokine family also play a role in 
suppressing inflammation by attracting anti-inflammatory subsets of monocytes and 
lymphocytes. (Prabhu & Frangogiannis, 2016) 
As the inflammation resolves, reparative processes take place and healing of the 
infarct wound begins. Myofibroblasts cannot be found in healthy myocardium but 
they appear after injury and are the most abundant cell type in infarct scar replacing 
the dead cardiomyocytes and contributing to the formation of the scar (Turner & 
Porter, 2013). Myofibroblasts resemble fibroblasts and smooth muscle cells and they 
express several contractile proteins (such as α-smooth muscle actin (SMA)), focal 
adhesion proteins (paxillin, tensin and αVβ3 integrin), cell surface receptors (TGF-β 
type II receptor and angiotensin AT1 receptor), structural ECM proteins (collagen I, 
collagen III and fibronectin), and matricellular proteins (periostin and 
osteopontin)(Turner & Porter, 2013). The contractile properties of myofibroblasts 
help in preventing infarct expansion (van den Borne et al., 2009). Myofibroblasts 
originate from several different cell types but the main source is most likely the 
resident fibroblasts that differentiate into myofibroblasts (Kanisicak et al., 2016; 
Yano et al., 2005). Endocardial epithelial cells can go through epithelial-
mesenchymal transition and endothelial cells endothelial-mesenchymal transition to 
adopt a myofibroblast phenotype. Also, mesenchymal stem cells, fibrocytes, smooth 
muscle cells and pericytes are thought to be sources of myofibroblasts (Turner & 
Porter, 2013). The differentiation of the fibroblasts into myofibroblast is initiated by 
mechanical stress when the integrity of the ECM is lost due to the injury. First the 
fibroblasts become proto-fibroblasts, which further differentiate into myofibroblasts 
in response to biochemical signals, especially TGF-β and fibronectin ED-A. 
Myofibroblasts can be found from infarct wounds years after the initial infarction. 
(van den Borne et al., 2009) 
The restoration of the ECM begins with formation of provisional matrix that is 
composed mainly of fibrin and fibronectin. It is highly plastic and functions as a 
scaffold for the healing tissue. Several matricellular proteins bind to matrix proteins 
and cell receptors transducing signalling cascades. They do not, however give 
mechanical support. The structural matrix components are produced by 
myofibroblasts; first type III collagen and later type I collagen (Turner & Porter, 
2013; van den Borne et al., 2009). 
Angiogenesis is a process where new microvessels sprout from the pre-existing 
vessels. The formation of new vessels is needed to provide oxygen and nutrients to 
the healing tissue. In addition to the granulation tissue where the healing takes place, 
angiogenesis also occurs in the surronding, viable myocardium (Cochain et al., 
2013). Angiogenesis is initiated by activation of HIFs in cardiomyocytes, endothelial 
Review of the Literature 
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cells, and inflammatory cells in the ischaemic area. HIFs induce the expression of 
angiogenic factors such as vascular VEGFs (Cochain et al., 2013). As a result, 
endothelial cells are activated, and changes in the basement membrane and 
endothelial cell junctions result in increased vascular permeability. The endothelial 
cells start to migrate guided by a specialised “tip cell”, which is followed by 
proliferating neighbouring endothelial cells that form the new sprout (Carmeliet & 
Jain, 2011). The sprouting of the new vessels begins from the infarct border zone 
(Zhao et al., 2010) and from the endocardium (Kobayashi et al., 2017), and then 
extends into the injured myocardium. The newly formed vessels are immature, leaky 
and disorganised before they enlarge and obtain a mural coat (Kobayashi et al., 
2017). The maturation of the vessels is mediated by platelet-derived growth factor 
(PDGF). (Cochain et al., 2013). 
Cells use adhesion molecules to interact with their surroundings and with other 
cells. One of the major groups of adhesion molecules is integrins which, during 
angiogenesis, mediate the adhesion between the tip cell and the ECM (Carmeliet & 
Jain, 2011). Integrins are heterodimeric transmembrane receptors, which consist of 
two glycoprotein subunits called α and β. Several different heterodimer 
combinations of 18 α and 8 β subunits form at least 24 integrin receptor variants in 
humans (Kim et al., 2011). Both α and β subunits have an intracellular domain that 
interacts with the cytoskeleton and an extracellular domain that interacts with ECM 
proteins. Thus, integrins act as linkers over the cell membrane between the cell 
cytoskeleton and ECM or adjacent cells facilitating cell adhesion and movement and 
serving as mechanotransducers. (Manso et al., 2009) Their role is not, however, only 
limited to mechanical adhesive functions, since they also participate in signalling in 
bidirectional manner, either outside-in or inside-out (Takagi et al., 2002). In concert 
with for example G-protein-coupled or kinase receptors, integrins mediate various 
processes such as cell proliferation, differentiation, gene expression profile and 
apoptosis. (Hynes, 2002) 
Depending on the subtype combination, integrins bind to several extracellular 
ligands, and reciprocally, one ligand can bind to several different integrins. Integrins 
can be divided into four distinct subfamilies based on the ligand recognition (Hynes, 
2002). These include tripeptide sequence RGD binding integrins, laminin binding 
integrins, collagen binding integrins and leukocyte specific integrins (Hynes, 2002; 
Ruoslahti & Pierschbacher, 1987). RGD was first found to be an integrin binding 
motif in fibronectin and since that, it has been found in several other adhesive ECM 
proteins (Ruoslahti & Pierschbacher, 1987). RGD-based ligands bind to many 
integrin heterodimers, albeit with varying selectivity, and have been utilised in 
diagnosis and treatment of several disease states involving angiogenesis (Kapp et al., 
2017). The ligand binding affinity of some integrins changes depending on the 
conformation of the integrin (Takagi et al., 2002). The trigger for the conformational 
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change from the inactive, bent conformation to the active, extended conformation 
comes from ligand binding or from the intracellular domains of the integrin receptor 
(Hynes, 2002). 
Myocardium expresses several integrins such as α5β1, αvβ1, αvβ3, and αvβ5, 
which regulate many processes during infarct healing and LV remodelling (Prabhu 
& Frangogiannis, 2016). They facilitate neutrophil adhesion to the endothelial cells 
on vessel wall before extravasation (Prabhu & Frangogiannis, 2016) and control 
macrophage activation (Antonov et al., 2011). Integrins activate latent TGF-β 
contributing to myofibroblast differentiation and cardiac fibrosis (Murray et al., 
2017; Sarrazy et al., 2014). Especially, the expression of αvβ3 integrin is related to 
infarct healing process, since its expression is low in healthy myocardium but 
upregulated in endothelial cells during angiogenesis (Brooks et al., 1994). The 
expression of αvβ3 integrin demonstrates subsequent functional recovery after MI 
in experimental and clinical studies (Jenkins et al., 2016; Sherif et al., 2012). 
2.1.3.3 Maturation phase 
During the maturation phase increased expression of crosslinking enzymes such as 
lysyl-oxidase promotes the crosslinking of the collagen. The reparative processes are 
run down and most of the reparative cells, such as myofibroblasts that have been 
active during the proliferative phase are inactivated or undergo apoptosis. By the end 
of the maturation phase the granulation tissue has matured into a dense collagen rich 
scar. (Prabhu & Frangogiannis, 2016) 
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Figure 1. Events and cell types during different phases of infarct healing. 
2.1.3.4 Adverse remodelling and heart failure 
The optimal result after the infarct healing process is a strong scar that can maintain 
the size and shape of the LV. When the healing is not optimal, adverse remodelling 
takes place, leading to changes in LV size, shape and function, and changes in 
cellular and biochemical functions (Prabhu & Frangogiannis, 2016). One of the key 
features during LV remodelling is LV dilatation which is an attempt to compensate 
for the cell loss and following contractile dysfunction of the LV. Dilatation increases 
the myocyte stretch and leads to hypertrophy which, at first, helps to maintain stroke 
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volume, but eventually promotes further dilatation and dysfunction (Pfeffer & 
Braunwald, 1990). The LV remodelling is characterised by regression of the gene 
expression profile back to a fetal gene profile, especially regarding thr genes related 
to metabolism and contractile proteins (Razeghi et al., 2001; Taegtmayer et al., 
2010). The initial purpose of all these changes is to compensate for the loss of the 
functioning myocardial tissue but instead they may lead to harmful effects, such as 
myocardial ischaemia and interstitial fibrosis, eventually resulting in the 
development of HF (Prabhu & Frangogiannis, 2016). The magnitude of adverse LV 
remodelling correlates with the extent of the myocardial injury (Chareonthaitawee 
et al., 1995; Wu et al., 2008), but also depends on other factors related to proper 
infarct healing (Westman et al., 2016). For example, impaired suppression of the 
inflammation and overactive fibrosis in the remote myocardium are predisposing 
factors to adverse remodelling. (Prabhu & Frangogiannis, 2016).  
Inflammatory response after MI is needed for proper infarct healing but 
subsequent suppression of inflammation is equally important as too strong or 
prolonged inflammatory response may lead to persistent myocardial damage and 
inadequate scar formation. The higher expression of the proinflammatory cytokines 
IL-6, TNF, and IL-1β have been linked to LV remodelling in preclinical studies (Ono 
et al., 1998). Many cytokines, chemokines and other inflammatory mediators that 
promote remodelling, however, may also have cardioprotective effects during the 
healing process making therapeutic interventions complicated. (Prabhu & 
Frangogiannis, 2016)  
Adequate density of myofibroblasts in the infarcted area is crucial for the 
formation of strong and flexible scar. Infarct expansion and LV dilatation with 
possible cardiac rupture occur when the amount of myofibroblasts in the infarcted 
region is too low. Too intense myofibroblast activation and collagen deposition 
especially in the remote myocardium, however, lead to myocardial stiffness and 
dysfunction. Several inflammatory cells, such as macrophages, mast cells and 
lymphocytes, activate myofibroblasts and fibrosis by secreting cytokines (for 
example TGF-β1 and IL-10) and matricellular proteins. (Frangogiannis, 2019; van 
den Borne et al., 2009). The activation of renin-angiotensin-aldosterone system 
(RAAS) contributes to the fibrosis during the adverse remodelling (Travers et al., 
2016). Angiotensin II activates myofibroblasts directly and also by stimulating TGF-
β1 production (Rosenkranz, 2004). TGF-β1 is the main contributor in fibrosis of the 
remote myocardium. It regulates myofibroblast differentiation and enhances the 
production of collagen, fibronectin and proteoglycans by cardiac fibroblasts 
(Rosenkranz, 2004). Both too high and too low myofibroblast density can lead to LV 
hypertrophy, reactive fibrosis, reduced cardiac output, arrhythmia and HF (Turner & 
Porter, 2013).  
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Sympathetic nervous system and RAAS become activated during the 
development of HF due to decrease in cardiac output. The activation of these 
neurohormonal systems and the changes they induce in other organs aim at keeping 
up the cardiovascular homeostatic balance but, in turn, contribute significantly to the 
progression of HF (Hartupee & Mann, 2016). HF is a condition where the heart is 
not able to pump blood efficiently enough for the metabolic needs of the body. The 
symptoms of HF are often non-specific, typically including shortness of breath and 
tiredness (Ponikowski et al., 2016). The diagnosis of HF relies on measurements of 
ECG, natriuretic peptides, and echocardiography. Other imaging modalities also 
may provide added value in uncertain cases (Ponikowski et al., 2016). Despite the 
developments in diagnosis and therapy, the prognosis of HF remains poor as more 
than half of the patients die within 5 years of the initial diagnosis. (Bleumink et al., 
2004; Johansson et al., 2016)  
2.1.4 Myocardial viability 
Dysfunctional ischaemic myocardium of patients with CAD often is a mixture of 
ischaemic but viable tissue and irreversibly injured scar tissue. In the presence of 
chronic or repetitive ischaemia, myocardium might go into the state of hibernation 
where the contractile function is missing and only the necessary metabolic activities 
are preserved in order to reduce the oxygen demand of the tissue and prevent 
myocyte necrosis (Rahimtoola, 1989; Ryan & Perera, 2018). The myocytes in 
hibernating myocardium are still alive i.e. viable and have the capability of regaining 
contractile function after revascularisation. Hibernation during myocardial 
ischaemia can be considered as a protective mechanism that keeps the myocytes 
alive. Hibernating myocardium increases the amount of glucose oxidative 
metabolism in order to produce enough ATP with less oxygen in comparison to 
oxidising fatty acids (Gewirtz & Dilsizian, 2017). Hibernating myocardium does not 
differ macroscopically from normal myocardium, but several histological, 
metabolic, and genetic changes have been found to take place. The cells switch from 
active contractile form to stable noncontractile form, which indicates cell 
dedifferentiation (Wijns et al., 1998). Microscopically, characteristics of 
dedifferentiation seen in the hibernating myocardium include loss of sarcomeres 
with aggregation of glycogen and mitochondria, loss of sarcoplasmic reticulum and 
redistribution of heterochromatin in the nucleus. (Wijns et al., 1998). The 
upregulation of genes related to cell survival, such as inhibitor of apoptosis (IAP), 
HSP70, H11 kinase (H11K), HIF-1α, VEGF and glucose transporter 1 (GLUT1), 
along with upregulation of related proteins, contribute to the survival of the myocytes 
from prolonged hibernation. (Depre et al., 2004). Even though the hibernation is a 
protective mechanism during ischaemia it can, however, become irreversible over 
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time as adaptive mechanisms become insufficient. It has been shown that the 
cardiomyocyte degeneration and fibrosis are more severe and functional recovery 
after revascularisation less likely after longer period of ischaemia (Elsasser et al., 
1997; Schwarz et al., 1998).  
Viable myocardium also may be stunned, which refers to a state where viable 
myocardium exhibits contractile dysfunction as a result from an episode of transient 
ischaemia. Stunned myocardium does not represent extracellular changes. In 
comparison to hibernation, which might take 6-12 months to recover, the contractile 
function in stunned myocardium recovers in a couple of weeks after the restoration 
of blood flow (Patel et al., 2018). 
2.2 Pig as an experimental model of chronic 
myocardial ischaemia 
Pigs are one of the most used translational non-rodent animal models in preclinical 
studies. The heart and the coronary artery system of pigs are almost identical to those 
of humans, which make the pig an ideal animal model for translational 
cardiovascular research. The heart-to-body weight ratio is identical in humans and 
in the typical 30 kg pigs, which are commonly used in cardiovascular studies 
(Lelovas et al., 2014). The similar size of the heart and blood vessels enables the use 
of clinical scanners and equipment, and more reliable discrimination between the 
injured and ischaemic myocardial areas than in rodents. Pigs do not have existing 
collateral flow and thus, serve as a better cardiovascular large animal model than for 
example dogs, which have more extensive collateral network and are thus more 
difficult to induce MI (Hearse, 2000). The lack of collateral flow in pigs, however, 
makes them susceptible to transmural infarction after the occlusion (Swindle et al., 
2012). Like humans, in normal conditions myocardium of pigs obtains most of its 
energy from free fatty acids, and in ischaemic conditions, by glucose metabolism 
(Lelovas et al., 2014). Also, infarct healing characteristics of pigs resemble humans 
more closely than many other species (Mehran et al., 1991). There are some 
limitations in the use of pigs. Growth rate of landrace pigs is high, which limits their 
use in long follow-up studies and might present some husbandry challenges. In 
regard of imaging studies, there might be problems with the limited size of the 
scanners. Pigs also tend to be vulnerable to ventricular arrythmias and sudden cardiac 
death. (Lelovas et al., 2014; Swindle et al., 2012) 
The most widely used methods to induce ischaemia in pigs usually are either 
surgical models most commonly using ameroid constrictor, or catheter-based 
percutaneous models (Hughes et al., 2003). The ameroid constrictor, composed of a 
hygroscopic inner ring, which is surrounded by a stainless-steel sheath, is placed 
around the coronary artery. The inner ring absorbs water and swells gradually 
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obstructing the lumen of the artery and resulting in reduction of the blood flow 
(Hughes et al., 2003). The placing of the ameroid constrictor requires thoracotomy, 
which is painful for the experimental animals and includes a risk for post-operative 
complications. Since pigs are susceptible to arrhythmias and sudden cardiac death 
after large MI, the model has been modified to include a distal ligation of the 
coronary artery before the placement of the ameroid constrictor, which improves the 
survival and produces larger infarcts (Teramoto et al., 2011). Surgical models also 
include fixed stenosis and hydraulic occluder-based models. The fixed degree of 
stenosis has an advantage of relatively similar degree of ischaemia in all pigs in 
comparison to ameroid constrictor model. Hydraulic occluder model also provides a 
fixed degree of stenosis, which can, however, be adjusted later. (Hughes et al., 2003) 
Percutaneous catheter-based methods have also been developed. The chronic 
ischaemia can be produced by bottleneck (Rissanen et al., 2013) or hourglass (Von 
Degenfeld et al., 2003) shaped stents, or with copper (Horstick et al., 2009) or 
copper-coated (Wu et al., 2010) stents. The latter ones are based on neointimal 
hyperplasia induced occlusion after the stent implantation. In the bottleneck and 
hourglass stent models, the occlusion of the stent can be modulated with antiplatelet 
medication, which keeps the stent open for the desired period (Rissanen et al., 2013; 
Von Degenfeld et al., 2003). Endovascular methods are less invasive and easier on 
the animals and have lower risk for post-operative complications. They also are less 
laborious and faster to perform. 
2.3 Myocardial perfusion imaging in ischaemic 
heart disease 
Myocardial perfusion, i.e. the blood flow through the myocardium can be assessed 
non-invasively using nuclear imaging techniques single photon emission computed 
tomography (SPECT) and PET, and computed tomography (CT), magnetic 
resonance imaging (MRI) and echocardiography. Myocardial perfusion imaging 
(MPI) is useful in detecting CAD and estimating the hemodynamic significance of 
the stenosis. The size and location of ischaemic areas can be detected when the MPI 
is performed in both rest and stress conditions. Mild coronary stenosis resulting in 
reversible ischaemia is characterised by normal myocardial blood flow (MBF) at rest 
and reduced MBF during stress. In the case of severe stenosis and scar tissue, also 
rest perfusion may be reduced. (Cademartiri et al., 2017; Coelho-Filho et al., 2013; 
Tweet et al., 2015) Stress during the scanning can be induced by physical exercise 
or by pharmacological vasodilators, such as adenosine, regadenoson or dipyridamole 
(Saab & Hage, 2017).  
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2.3.1 Myocardial perfusion imaging with PET 
MPI with PET is a standard tool in assessing perfusion defects in patients with CAD 
(Saraste et al., 2012). PET is a non-invasive molecular imaging technique based on 
the use of radiotracers at concentrations that do not affect biological processes. PET 
radiotracers consist of a molecular structure that is attached to a short half-life 
positron emitting radioisotope (Wadsak & Mitterhauser, 2010). When the 
radioisotope decays, it emits a positron that travels a short distance in the tissue 
before meeting an electron. Upon collision, positron and electron annihilate and 
produce two 511 keV gamma rays that travel in opposite directions and can be 
detected with the PET scanner’s detectors that surround the subject circularly. The 
raw data from the scanner can then be reconstructed into an image using dedicated 
software (Phelps, 2000). An MPI PET tracer is retained in the myocardium 
proportional to blood flow and the myocardial blood flow can be measured at rest 
and under stress conditions to delineate the severity and extent of myocardial 
ischaemia. PET MPI tracers have relatively short physical half-lives and, therefore, 
the stress in PET studies needs to be induced by pharmacological agents. The unique 
feature of PET perfusion imaging is that blood flow can be quantified in absolute 
terms, i.e. in ml/g/min. This enables separate quantitation of MBF in each vascular 
territory and detection of three-vessel disease in which the MBF is reduced in all 
vascular territories. The quantification may, however, be limited to some extent by 
the perfusion dependent extraction fraction of some tracers (Figure 2). This results 
in non-linear tracer uptake and underestimation of higher flows, which can be 
corrected by mathematical models. The most commonly used PET perfusion tracers 
are partially extracted tracers [13NH3] and [82Rb], and freely diffusible tracer 
[15O]water. (Driessen et al., 2017; Knuuti et al., 2009; Maddahi & Packard, 2014; 
Saraste et al., 2012) 
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Figure 2. Relationship between absolute myocardial blood flow and tracer uptake (By Roel S. 
Driessen et al. (2017). "Myocardial perfusion imaging with PET". International Journal 
of Cardiovascular Imaging 33 (7): 1021–1031. DOI:10.1007/s10554-017-1084-4. PMC: 
5489578., Wikimedia commons, CC BY 4.0) Accessed on 12.12.2019. 
[13NH3] diffuses freely across cell membranes into the myocardial cells but is then 
converted to [13N]glutamine by glutamine synthase, and trapped inside the cells. It 
has a high extraction fraction that changes only little with higher flows. The physical 
half-life of [13NH3] is approximately 10 minutes making an on-site or a nearby 
cyclotron prerequisite. (Muzik et al., 1993; Schelbert et al., 1981)  
Potassium analog [82Rb] is actively transported into the myocytes by Na/K ATP 
transporter. The physical half-life of [82Rb] is 76 seconds and it has a relatively low 
and flow-dependent extraction fraction, which needs to be corrected with modelling. 
It is, however, widely used due to its relatively easy availability with generator 
production (Saraste et al., 2012). 
[15O]water is a metabolically and chemically inert, freely diffusible tracer with a 
flow-independent extraction fraction of practically 1, leading to a linear relationship 
between the myocardial uptake and MBF. Due to its ideal characteristics, [15O]water 
is considered the golden standard for quantification of myocardial perfusion and it 
detects myocardial ischemia with high diagnostic accuracy (Danad et al., 2014, 
2017). A one-tissue compartment model is used in the [15O]water analysis. The 
quantification of segmental MBF with [15O]water can be done  with good 
reproducibility using different scanners and softwares (Harms et al., 2014). Also, 
perfusable tissue fraction (PTF) and perfusable tissue index (PTI) can be obtained 
from the [15O]water scan. PTF is the amount of the tissue in the region of interest 
(ROI) that is capable of exchanging water rapidly, whereas PTI is the ratio of PTF 
and anatomical tissue fraction (ATF), which represents the mass of extravascular 
tissue inside the ROI. Thus, PTI is the fraction of the extravascular tissue that is 
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perfused by water. ATF is obtained by blood pool imaging with [15O]CO or by 
calculating parametric PTI images. (Harms et al., 2011; Iida et al., 1988, 1991) Due 
to the physical half-life of 123 seconds, [15O]water production is dependent on an 
on-site cyclotron.  
A novel PET perfusion tracer [18F]flurpiridaz is currently undergoing phase III 
trial. It binds to mitochondrial complex-1 and is rapidly taken up by myocytes and 
retained in cardiomyocytes. [18F]flurpiridaz has a high extraction fraction and it has 
shown good results in clinical trials in relation to safety and in the detection of CAD. 
In comparison to other PET perfusion tracers, [18F]flurpiridaz has a physical half-
life of 110 minutes, enabling transport and use also in imaging centres without an 
on-site cyclotron. In contrast to other PET perfusion tracers, [18F]flurpiridaz is useful 
with both pharmacological and exercise stress tests due to its longer half-life 
(Berman et al., 2013; Yalamanchili et al., 2007; Yu et al., 2007). 
All of the above-mentioned PET MPI tracers have their advantages and 
disadvantages, and none meets all of the criteria for an optimal PET MPI tracer 
(Maddahi, 2012). The different characteristics of PET perfusion tracers are 
summarised in Table 1. 
Table 1  Characteristics of PET perfusion tracers. 
 [15O]water [13NH3] [82Rb] [18F]flurpiridaz 
Physical half-life 123 s 10 min 76 s 110 min 
Production Cyclotron Cyclotron Generator Cyclotron 
Kinetics Freely diffusible, 
metabolically 
inert 
Metabolically 
trapped in the 
myocardium 
Metabolically 
trapped in the 
myocardium 
Metabolically 
trapped in the 
myocardium 
Max positron 
energy (keV) 
1732 1198 3356 634 
Positron range 
(mm) 
4.14 2.53 8.6 1.03 
Myocardial 
extraction fraction 
(%) 
100 80 65 94 
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2.4 Imaging of myocardial viability 
Since viable but dysfunctional myocardium can recover contractile function after 
revascularisation, the detection of viable myocardium is important in identifying the 
patients that benefit most from revascularisation. Viability imaging can be used to 
predict the probability of the myocardium to recover after revascularisation. If the 
patient does not have viable myocardium in the ischaemic area, the risks related to 
revascularisation procedures most likely outweigh the benefits. It has been shown 
that almost 40% of the patients who have ischaemic LV dysfunction exhibit 
improvement in LV function after revascularisation (Schinkel et al., 2004). Various 
non-invasive imaging techniques can be used to detect viable myocardium. The 
choice of the method should depend on the local expertise and availability, and on 
the additional information that is needed in addition to viability, since all the imaging 
modalities target different characteristics (Windecker et al., 2014). The assessment 
of viability alone is not meaningful but should be used in combination with the 
assessment of other variables for a comprehensive evaluation of patients. The main 
techniques for non-invasive assessment of myocardial viability are SPECT, PET, 
echocardiography, and cardiac magnetic resonance (CMR). The characteristics of 
different imaging techniques and their performance in the prediction of functional 
improvement are summarised in Table 2. (Bax & Delgado, 2015; Schinkel et al., 
2007).  
2.4.1 SPECT 
Potassium analog 201Th, and 99mTc labelled compounds sestamibi and tetrofosmin 
are the most widely used SPECT tracers for the assessment of myocardial viability. 
The detection of viable tissue with 201Th is based on perfusion and integrity of the 
cell membrane. After injection, the initial uptake of 201Th reflects perfusion. The 
washout of 201Th is quite fast and depends on MBF. Myocardial viability can be 
assessed from delayed images as 201Th redistributes depending on the functional 
Na+/K+ ATPase pump on myocyte cell membrane. (Henzlova et al., 2016; 
McDiarmid et al., 2017)  
In comparison to 201Th, tracers labelled with 99mTc have better image quality 
because they emit higher energy photons. The assessment of myocardial viability 
with [99mTc]tetrofosmin and [99mTc]sestamibi depends on perfusion, cell membrane 
integrity and functional mitochondrial membranes. Sestamibi and tetrofosmin 
distribute passively across the membranes and bind to mitochondria where they are 
retained due to negative mitochondrial charge gradient, which is present only in 
viable myocytes (Caner & Beller, 1998; Henzlova et al., 2016). 
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2.4.2 PET 
Glucose analog [18F]FDG is the most commonly used PET tracer and it is used to 
visualise glucose metabolism in cells. Like glucose, [18F]FDG is taken up by the cells 
via glucose transporters and then phosphorylated to FDG-6-phosphate. After 
phosphorylation, however, the tracer cannot proceed to the next steps of the 
glycolytic pathway and is trapped inside the myocytes. In normal conditions 
myocardium produces ATP mainly by oxidising free fatty acids but in an ischaemic 
myocardium the energy is obtained mainly by glucose metabolism and glucose 
transporters are upregulated. Since [18F]FDG is transported into the cells via glucose 
transporters, the upregulation of the transporters in ischaemic myocardium results in 
elevated uptake of [18F]FDG. (Bax et al. 2000) Viability imaging with [18F]FDG is 
combined with the assessment of perfusion. The detection of viable myocardium is 
based on a perfusion-metabolism mismatch, meaning elevated [18F]FDG uptake in 
combination with perfusion defect, while in scar tissue the [18F]FDG uptake and 
perfusion are both decreased. (Tillisch et al., 1986) 
Also, PTF and PTI derived from the measurement of MBF by [15O]water PET, 
have been studied to evaluate viability. Since scar tissue cannot exchange water 
rapidly, PTF and PTI both are reduced in the absence of viable tissue (Iida et al., 
2000; Knaapen et al., 2003, 2006). They both have been shown to detect viability 
and predict recovery of contractile function after revascularisation in patients with 
acute (Timmer et al., 2017; Yamamoto et al., 1992) or old MI (Bondarenko et al., 
2011; de Silva et al., 1992; Iida et al., 2012; Itoh et al., 2002). 
The oxidative metabolism and perfusion can be imaged with 11C-labelled acetate. 
Acetate is quickly transported into myocytes and converted into acetyl-CoA. The 
build-up phase of the radioactivity after the injection of [11C]acetate is related to 
perfusion. Acetyl-CoA is further oxidised to CO2 in the tricarboxylic acid cycle in 
mitochondria. The clearance rate of [11C]CO2 from the tissue represents the oxygen 
consumption and is higher in the viable than in the non-viable myocardium. (Grassi 
et al., 2012; Klein et al., 2001) 
2.4.3 Echocardiography 
The use of echocardiography in the viability assessment is mainly based on the 
detection of contractile reserve during dobutamine stress. Dobutamine infusion is 
started with a low dose and increased gradually. Viable but ischaemic myocardium 
exhibits a biphasic response to stepwise infusion of dobutamine. The contractile 
dysfunction improves during low dose infusion if the tissue is viable but is then 
followed by worsening as the dose is increased (Senior & Lahiri, 1995). The end 
diastolic wall thinning (EDWT) can be assessed from resting echocardiograpy 
images. The LV wall thickness may be reduced in the areas of transmural infarction, 
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and a thickness of ≤ 6 mm seems to exclude fuctional recovery after revascularisation 
(Cwajg et al., 2000). 
2.4.4 Cardiac magnetic resonance imaging 
Several CMR techniques have been used for the assessment of myocardial viability.  
Like with dobutamine stress echocardiography, contractile reserve can be detected 
with CMR during dobutamine infusion. CMR also allows detection of the transmural 
extent of the scar using gadolinium-based contrast agents, which stay in the 
interstitial space in the tissue. Scar tissue has more interstitial space and thus 
enhancement of gadolinium can be seen in the scar area. Also, EDWT associated 
with transmural scar can be detected with CMR. (Kaandorp et al., 2005) 
Table 2  Characteristics of different techniques for assessment of myocardial viability. 
Sensitivities and specificities from Schinkel et al. 2007. 
Technique Imaging finding Prediction of improvement 
in regional function 
  Sensitivity 
(%) 
Specificity 
(%) 
SPECT    
• [201Th] Perfusion, cell membrane integrity 87 54 
• [99mTc] Perfusion, cell membrane 
integrity, intact mitochondria 
83 65 
PET    
• [18F]FDG Glucose metabolism 92 63 
• [15O]water PTF, PTI   
• [11C]acetate Oxidative metabolism, perfusion   
Dobutamine stress 
echocardiography 
Contractile reserve 80 78 
Cardiac magnetic 
resonance imaging 
   
• Resting End diastolic wall thickness 95 41 
• Dobutamine infusion Contractile reserve 74 82 
• Gadolinium based 
contrast agents 
Scar tissue 84 63 
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2.5 PET imaging of myocardial injury and 
angiogenesis 
PET imaging of different molecular processes that are related to infarct healing and 
LV remodelling provide potential tools in detecting the patients who are at higher 
risk for developing HF after MI. Additionally, they may provide help in planning of 
the treatments. PET tracers for different infarct healing characteristics are 
summarised in Table 3. 
2.5.1 Inflammation 
Inflammatory response after MI is complex and closely linked to the reparative 
actions. Since many characteristics of inflammatory response have both beneficial 
and detrimental roles during the infarct healing depending on their temporal 
occurrence, selective detection of injurious characteristics is needed to guide 
therapeutic approaches aiming to modulate inflammatory response.  
[18F]FDG is the mostly used PET tracer in imaging inflammation in various 
diseases. Myocardium shows increased [18F]FDG uptake after MI. The uptake seems 
to be localised on monocytes and macrophages by a preclinical study (Lee et al., 
2012), and correlate inversely with functional outcome in patients 6 months after the 
MI (Rischpler et al., 2016). Ischaemic myocardium obtains energy from glucose 
metabolism and remaining viable cardiomyocytes can show high [18F]FDG uptake. 
To prevent the unspecific uptake patients can be subjected to high fat diet, fasting, 
and heparin injection prior to the scan. (Rischpler et al., 2016) 
[11C]methionine uptake reflects protein synthesis and amino acid transport but it 
also accumulates into sites of inflammation and tissue repair. [11C]methionine 
accumulates in the infarcted area at early phase of infarct healing in experimental 
animals and humans.  The accumulation seems to be localised in proinflammatory 
M1 macrophages. (Morooka et al., 2009; Thackeray et al., 2016). 
Another possible target for PET imaging of inflammation is the chemokine 
receptor CXCR4, which is involved in recruitment and homing of stem cells and 
leukocytes into the infarcted region. CXCR4 binding PET tracer [68Ga]pentixafor 
has been studied after MI in preclinical studies and in patients. In mice the infarcted 
area shows higher tracer uptake, which corresponds with leukocytes (Thackeray et 
al., 2015). Patients have shown high interindividual variability in the 
[68Ga]pentixafor uptake (Lapa et al., 2015) but it, however, has been shown to 
correlate with smaller scar volume after healing (Reiter et al., 2018). 
There is some limited evidence of imaging post-infarction inflammation with 
mitochondrial translocator protein (TSPO) targeted tracers. The uptake of 
[18F]GE180 has been shown to detect inflammation early after infarction and predict 
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later occurrence of LV remodelling. Later uptake is not related to inflammatory cells, 
suggesting myocyte mitochondrial impairment (Thackeray et al., 2018).  
2.5.2 Angiogenesis 
The expression of αvβ3 integrin is normally low in endothelial cells but highly 
upregulated during angiogenesis, making it a potential target for imaging 
postinfarction angiogenesis (Brooks et al., 1994). In addition to mediating 
angiogenesis, αvβ3 integrin also plays a role in the regulation of other characteristics 
of the infarct healing process, such as macrophage inflammatory responses and 
myofibroblast differentiation (Antonov et al., 2011; Sarrazy et al., 2014). Tripeptide 
sequence RGD is an integrin binding motif that can be radiolabelled and used in the 
detection of αvβ3 integrin expression after MI (Gao et al., 2012; Higuchi et al., 2008; 
Kiugel et al., 2014; Laitinen et al., 2013; Menichetti et al., 2013; Sherif et al., 2012). 
The RGD tracer uptake is visible already 3 days after the infarction, peaks between 
1 and 4 weeks, and stays in the detectable level even for 6 months after the MI 
(Higuchi et al., 2008; Kiugel et al., 2014; Meoli et al., 2004). The elevated uptake of 
RGD based tracers has been shown to be associated with the absence of significant 
LV remodelling after experimental MI (Sherif et al., 2012), and probability of 
functional recovery in patients with acute MI (Jenkins et al., 2016). Tracers 
containing RGD motif also provide a potential tool for monitoring the effects of 
angiogenesis inducing therapies (Cai et al., 2016; Johnson et al., 2008). The use of 
RGD peptides has been evaluated not only for imaging angiogenesis, but also other 
characteristics of LV remodelling such as myofibroblasts (van den Borne et al., 
2008). 
While αvβ3 integrin targeted RGD tracers are the most studied angiogenesis 
imaging probes, also some other angiogenesis related targets, for example α5β1 
integrin, CD13, CD105 and VEGF, have been preclinically evaluated (Mandic et al., 
2016; Orbay et al., 2013). 
2.5.3 Fibrosis 
CMR is the most used method for detecting myocardial fibrosis but PET enables 
specific assessment of the molecular processes related to the formation of fibrosis. 
Activated RAA system is an important mediator in the formation of fibrosis 
contributing to myofibroblast differentiation through activation of TGF-β, thus 
providing a potential target for the assessment fibrosis. An angiotensin-converting 
enzyme (ACE) inhibitor [18F]fluorobenzoyl-lisinopril has been tested in human 
explanted hearts where it binds specifically to ACE in the areas adjacent to collagen 
replacement (Dilsizian et al., 2007). [11C]KR31173 is a tracer that binds to 
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angiotensin II subtype 1 receptors (AT1R). It has been shown to accumulate in the 
ischaemic and remote myocardium after MI in pigs. The first clinical study also 
showed accumulation in the healthy heart, although at lower level than pigs 
(Fukushima et al., 2013). ACE is an excreted enzyme, which makes it less suitable 
as an imaging target than receptors such as AT1R or TGF-β (van den Borne et al., 
2009). Some TGF-β targeted tracers already exist, but they have not been assessed 
in MI (Rotteveel et al., 2019). 
Table 3  Established and experimental PET tracers for imaging different characteristics of infarct 
healing process 
Characteristic Tracer Target 
Inflammation [18F]FDG Monocytes and macrophages 
 [11C]methionine Proinflammatory M1 
macrophages 
 [68Ga]pentixafor CXCR4 chemokine receptor 
 [18F]GE180 Mitochondrial translocator 
protein (TSPO) 
Angiogenesis RGD αvβ3 integrin 
  α5β1 integrin 
  CD13 
  CD105 
  VEGF 
Fibrosis [18F]fluorobenzoyl-lisinopril ACE 
 [11C]KR31173 AT1R 
  TGF-β 
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3 Aims 
The purpose of this study was to develop new translational technology for non-
invasive imaging of myocardial ischaemic injury based on quantification of 
perfusion and molecular targeting of angiogenesis in large animal models that 
closely resemble human ischaemic heart disease. Furthermore, we aimed at 
validating molecular targeting of angiogenesis in an angiogenesis tissue model. The 
individual aims of the three studies in this thesis were:  
 To evaluate resting MBF, PTF, and PTI measured with [15O]water PET 
for the detection of infarcted and viable myocardium in comparison to 
histology in experimental models of chronic myocardial infarction. 
 To study the feasibility of non-invasive imaging of integrin expression 
with the use of [68Ga]NODAGA-RGD PET after reversible or irreversible 
chronic ischaemic myocardial injury in the pig heart. 
 To quantitate the [68Ga]NODAGA-RGD uptake in comparison to the 
amount of angiogenesis in human cell-based 3D in vitro model of 
angiogenesis. 
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4 Materials and Methods 
4.1 Animal models (I, II) 
Finnish landrace pigs were used in the animal experiments. All animal experiments 
were approved by the Lab-Animal Care & Use Committee of the State Provincial 
Office of Southern Finland and carried out in compliance with the EU legislation 
relating to the conduct of animal experimentation. 
4.1.1 Study outline (I, II) 
In subproject I, 20 pigs with a TTC confirmed MI and PET myocardial perfusion 
imaging performed were retrospectively evaluated. 4 pigs were implanted with a 
bottleneck stent in the proximal LAD, and 16 pigs underwent a 2-step occlusion of 
LAD. Pigs were imaged with [15O]water at rest 2 weeks or 3 months after the stenting 
or surgical operation, respectively. Then, hearts were excised and stained with TTC. 
In subproject II, 11 pigs were implanted with a bottleneck stent in the proximal 
LAD. 2 weeks after the stent implantation, pigs were imaged with [15O]water at rest 
and during adenosine-induced stress, and with [68Ga]NODAGA-RGD. Three pigs 
with no perfusion defect during stress were excluded from further analyses. After 
imaging, the hearts were excised for immunohistochemical stainings and ex vivo 
analyses.  
4.1.2 Anaesthesia and hemodynamic monitoring (I, II) 
The animals were anaesthetised with intramuscular (i.m) injection of midazolam 1 
mg/kg (Midazolam Hameln, Hameln Pharmaceuticals GmbH, Hameln, Germany) 
and xylazine 4 mg/kg (Rompun vet, Bayer Animal Health GmbH, Leverkusen, 
Germany). Anaesthesia was maintained with intravenous (i.v.) infusion of propofol 
10−50 mg/kg/h (Propofol-Lipuro, B. Braun Melsungen AG, Melsungen, Germany) 
combined with fentanyl 4−8 µg/kg/h (Fentanyl-Hameln, Hameln Pharmaceuticals 
GmbH, Hameln, Germany) via cannulated ear vein under mechanical ventilation 
with tidal volume of 8-10 ml/kg and frequency of 14-18 breaths per minute (Dräger 
Oxylog 3000, Drägerwerk AG, Lübeck, Germany). Diastolic, systolic, and mean 
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arterial pressure and heart rate were recorded via cannulated femoral artery using a 
pressure transducer (TruWave, Edwards Lifesciences, Irvine, CA, USA).  
4.1.3 Bottleneck stent model for myocardial ischaemia (I, II) 
The implantation of the bottleneck stent has been previously described (Rissanen et 
al., 2013). First, an introducer sheath (6F, Cordis, Bridgewater, NJ, USA) was placed 
percutaneously in the femoral artery. Pigs were catheterized with a GE Innova 3100IQ 
3D angiography device (GE Healthcare, Waukesha, WI, USA). A sterilized 
polytetrafluoroethylene tube (diameter 5/64 in.; Fluorplast, Petalax, Finland) with a 
bottleneck diameter of 0.9 mm on the other end of the tube on a Coroflex Blue Ultra 
(B. Braun Medical; profile 0.8 mm) bare metal stent was placed into the proximal 
left anterior descending (LAD) coronary artery. A Femostop device (St. Jude 
Medical, St. Paul, MN, USA) was used to secure hemostasis after the removal of the 
sheath. 
Amiodarone 200 mg/day per orally (p.o.) (Cordarone, Sanofi, Paris, France) and 
bisoprolol 2.5 mg/day p.o. (Bisoproact, Actavis Group, Hafnarfjordur, Island) were 
administered starting 1 week before the stenting until the end of the study to prevent 
arrhythmias. 750 mg i.v. bolus of Cefuroxime (Zinacef, GlaxoSmithKline, 
Brentford, UK), 100 mg i.v. bolus of lidocaine (Lidocain, Orion Corporation, Espoo, 
Finland) and 2.5 ml i.v. bolus of magnesium sulphate (246 mg/ml, Addex-
magnesiumsulfaatti, Fresenius Kabi AB, Uppsala, Sweden) were administered 
immediately before the catheterization. Acetylsalicylic acid 300 mg p.o. (Primaspan, 
Orion Corporation, Espoo, Finland) was given 1 day before stenting and daily dose 
of 100 mg p.o. was continued throughout the study. Also clopidogrel 300 mg p.o. 
(Plavix, Sanofi, Paris, France) was given 1 day before stenting and continued 
throughout the study with a dose of 75 mg/day p.o. Enoxaparin 30 mg i.v. (Sanofi, 
Paris, France) was administered after the insertion of an introducer sheath in the 
femoral artery, and another 30 mg was given subcutaneously (s.c.) after removing 
the sheath and securing hemostasis. Daily dose of enoxaparin (30 mg/day s.c.) was 
continued throughout the study. 
4.1.4 Ameroid model (I) 
A two-step ligation of LAD was performed surgically. Short left anterior 
thoracotomy was performed and pericardium was opened. Complete ligation of the 
distal LAD was first performed using a 5-0 monofilament polypropylene suture 
(Prolene, Ethicon, Norderstedt, Germany). Approximately 15 minutes after the 
ligation of distal LAD, an ameroid constrictor (2.50 or 2.75 mm, model MRI-2.50-
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TI and MRI-2.75-TI; Research Instruments SW, Escondido, CA, USA) was placed 
around the proximal LAD.  
Pigs were administered 30 mg/kg i.v. bolus of cefuroxime (Cefuroxime, Orion 
Pharma, Espoo, Finland) before the operation. The thoracotomy wound was 
anaesthetized with 25 mg i.m. injection of bupivacain (Bicain, Orion Pharma, Espoo, 
Finland) at the end of the operation. Fentanyl 2-4 µg/kg/hour (Matrifen transdermal 
patch, Takeda Pharma A/S, Roskilde, Denmark) was administered postoperatively 
for 3-7 days.  
Amiodarone (Cordarone, Sanofi-Synthelabo Ltd., Newcastle upon Tyne, UK) 
was administered 8 mg/kg perorally (p.o.) daily starting 1 week before and lasting 
for 2 weeks after the surgery. Amiodarone 6 mg/kg i.v., metoprolol 2 mg/kg i.v. 
(Seloken, Genexi, Fontenay sous Bois, France) and magnesium sulfate (MgSO4) 25 
mg/kg i.v. (Addex-magnesiumsulfaatti, Fresenius Kabi AB, Uppsala, Sweden) were 
intraoperatively administered. Administration of Clopidogrel 3 mg/kg p.o. (Plavix, 
Sanofi Winthrop Industrie S.A., Ambare`s et Lagrave, France) was started 1 day 
before and continuing for 2 weeks after the surgery to prevent premature thrombosis 
of the LAD. 
4.2 In vivo PET studies 
4.2.1 Imaging myocardial perfusion with [15O]water PET (I, II) 
In study I, the myocardial perfusion PET study with [15O]water at rest was performed 
2 weeks after the stent implantation or 3 months after the surgical operation, and in 
study II, the myocardial perfusion studies at rest and under pharmacological stress 
were performed 2 weeks after the stent implantation with a Discovery 690 hybrid 
PET/CT scanner (GE Medical Systems, Milwaukee, WI, USA). [15O]water was 
injected as an i.v. bolus over 15 s at an infusion rate of 10 ml/min via the ear vein. A 
4 min 40 s dynamic scanning was performed with time frames 14 × 5 s, 3 × 10 s, 3 
× 20 s and 4 × 30 s. An adenosine infusion at the rate of 200–500 µg/kg/min 
combined with phenylephrine 5 µg/kg/min was started 120 s before the [15O]water 
injection and continued until the end of the scan. The acquired [15O]water PET data 
were corrected for scatter, random counts and dead time. An iterative VUE Point 
algorithm using 2 iterations and 24 subsets was used for reconstruction. The whole 
transaxial field of view (70 cm) was reconstructed in 128 × 128 matrix yielding pixel 
size of 5.47 mm × 5.47 mm. The device produces 47 axial planes with a slice 
thickness of 3.27 mm. 
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4.2.2 Imaging integrin expression with [68Ga]NODAGA-RGD 
(II) 
[68Ga]NODAGA-RGD PET was performed with an ECAT EXACT HR+ scanner 
(Siemens-CTI, Knoxville, TN, USA) right after the [15O]water studies.  After a 10 
min transmission scan, 310 ± 43 MBq of [68Ga]NODAGA-RGD was injected via the 
ear vein. The 62 min dynamic scanning (aquisition time frames: 18 × 10 s, 4 × 30 s, 
2 × 120 s, 1 × 180 s, 4 × 300 s and 3 × 600 s) started at the same time with the tracer 
injection. The acquired [68Ga]NODAGA-RGD PET data were corrected for scatter, 
random counts, and dead time and iteratively reconstructed with ordered-subsets 
expectation maximization (OSEM) algorithm using 2 iterations and 32 subsets. The 
whole transaxial field of view (70 cm) was reconstructed in 256 × 256 matrix 
yielding to pixel size of 2.57 mm × 2.57 mm. The device produces 63 axial planes 
with a slice thickness of 2.43 mm. 
4.2.3 PET image analyses (I, II) 
Carimas 2.9 software with Heart and PolarRoi plug-in tools (Turku PET Centre, 
Turku, Finland) was used for the analyses of the PET images. In [15O]water images, 
the long axis was manually defined and the myocardial contours were semi-
automatically defined and the volume of interest (VOI) covering the whole LV 
myocardium was applied. The PTF and absolute segmental LV MBF were quantified 
from [15O]water data as ml/min/g using a single-compartment model as described 
earlier (Iida et al., 1991, 1992), and displayed as a standard 17 segment polar map. 
(I, II) 
To obtain the relative MBF values in study I, the polar maps of [15O]water at rest 
were normalised to mean value of four posterolateral segments (segments 4, 5, 10, 
and 11), which were outside the ischaemic area. Posterolateral segments that were 
infarcted according to 2,3,5-triphenyltetrazolium chloride (TTC) staining, were 
excluded from the mean value. To study the reproducibility of the measurements, 
the analyses were performed twice by the same observer, and within-subject 
coefficients of variations were calculated by using root-mean-square approach. 
Coefficients of variations for repeated measurements of absolute MBF, relative 
MBF, and PTF measurements were 6% in the remote non-infarcted segments. In 
segments with infarct volume fraction ≥ 75%, coefficients of variations were 19%, 
18%, and 10%, respectively.  
In transmurally infarcted myocardium the thickness of the LV wall may be 
reduced. The effect of ROI thickness on absolute MBF, relative MBF, and PTF was 
evaluated by manually increasing or reducing ROI thickness from default. In further 
analyses, ROI thickness was manually reduced to completely fit inside the 
myocardium. MBF and PTF in viable and non-viable myocardium of the pigs that 
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had transmural infarction were further compared by analysing their circumferential 
profiles in 48 sectors in midventricular level. Values were compared between the 
transmurally infarcted non-viable area (average of three adjacent sectors) and remote 
viable areas (average of six sectors). For PTI measurements, a subset of pigs were 
further analysed with aQuant software (MedTrace Pharma A/S, Denmark) as 
described earlier (Harms et al., 2011).  
In study II, for quantification of [68Ga]NODAGA-RGD uptake in the 
myocardium, the [15O]water images and the [68Ga]NODAGA-RGD images were co-
registered using the high blood pool activity of the [68Ga]NODAGA-RGD as a 
landmark (Figure 3). The myocardial contours from the [15O]water images were 
copied to the co-registered [68Ga]NODAGA-RGD data. Then, the polar maps of 
[68Ga]NODAGA-RGD uptake expressed as standardized uptake value (SUV) (time 
frame 52–62 min after injection) in the LV myocardium were generated. The ROI 
defining the ischaemic area (region with myocardial blood flow less than 80% of 
maximum during adenosine-induced stress as previously described (Kajander et al., 
2011)) was copied from the [15O]water polar maps to measure [68Ga]NODAGA-
RGD uptake in this region. The septum was excluded from the measurements to 
prevent spill over from the blood in the right ventricle. The mean and maximum 
SUVs were determined from the ischaemic area. In order to measure the SUVs, ROI 
was modified to include only the mid-myocardium in order to avoid spill-over from 
blood. The maximum SUV within the ROI was determined from area showing 
visually the highest uptake. One segment in the posterolateral wall (segment 11) that 
was always outside the ischaemic area was used to measure [68Ga]NODAGA-RGD 
uptake in the remote myocardium. The ischaemic-to-remote SUV ratio was 
calculated in the ischaemic area and remote myocardium. 
 
Figure 3. Co‑registration of [68Ga]NODAGA‑RGD and [15O]water PET images. Panels a and f 
demonstrate [68Ga] NODAGA‑RGD images during the first 2 min after injection of the 
tracer, and panels e and j during the last 20 min of the imaging session. Panels c and h 
demonstrate [15O]water PET images, which are fused with [68Ga]NODAGA‑RGD images 
at different time points in images b and g, and d and i. From original publication II. 
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4.3 Tissue analyses 
The pigs were sacrificed after the PET scanning with an i.v. injection of potassium 
chloride (B. Braun Medical Oy, Helsinki, Finland). The heart was excised, and LV 
was cut into 4 short axis slices from base to apex. 
4.3.1 TTC (I, II) 
To visualize the non-viable ischaemic area, LV slices were incubated for 15 min in 
1% TTC (Sigma-Aldrich, Saint Louis, MO, USA), diluted in phosphate-buffered 
saline (PBS) (pH 7.4) at 37 °C and photographed from both sides. TTC staining 
differentiated between metabolically active viable and metabolically inactive non-
viable tissue. TTC stains viable tissue deep red and leaves the non-viable tissue pale, 
almost white.  
In study I, the infarct size was estimated from the TTC photographs visually. The 
heart was divided into segments using a standard 17 segments division. The volume 
fraction of the infarct in each segment was categorized as follows: 0: no infarct; 1: 
infarct size < 25%; 2: 25% – < 50%; 3: 50% – < 75%, and 4: ≥ 75% of the size of 
the segment. The apical segment 17 was excluded from the analyses. 
In study II, transmural samples were collected according to the TTC staining 
from the non-viable area, immediately adjacent viable area, and from the remote area 
in the posterior LV wall. 
4.3.2 Ex vivo autoradiography (II) 
Tissue samples from the non-viable area, immediately adjacent viable area, and from 
the remote area were frozen in isopentane and cut into 40 µm sections for 
autoradiography. Sections were immediately exposed on a phosphor imaging plate 
(BAS-TR2025, Fuji Photo Film Co. Ltd., Tokyo, Japan) for two hours. After 
exposure the plates were scanned with Fluorescent Image Analyzer (Fujifilm FLA-
5100, Fuji Photo Film Co. Ltd., Tokyo, Japan). The distribution of [68Ga]NODAGA-
RGD was measured by drawing ROIs covering remote myocardium, and viable or 
injured ischaemic myocardium using TINATM 2.10f software (Raytest 
Isotopenmessgeräte GmbH., Straubenhardt, Germany). Results were expressed as 
photostimulated luminescence per square millimetre (PSL/mm2) and normalized for 
the injected radioactivity dose, animal weight and the radioactivity decay. 
4.3.3 Ex vivo biodistribution (II) 
Myocardial samples from the non-viable area, immediately adjacent viable area, and 
from the remote area in the posterior LV wall were weighed and measured for 
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radioactivity using the gamma counter (Wizard 3”; PerkinElmer/Wallac, Turku, 
Finland). The radioactivity concentration was expressed as standardized uptake 
values (SUV = ([tissue radioactivity/tissue weight]/[total given radioactivity/animal 
body weight])).  
4.3.4 Histology and immunohistochemistry (II) 
4.3.4.1 General histology 
Frozen sections of 7 μm of myocardial samples from the non-viable area, 
immediately adjacent viable area, and from the remote area in the posterior LV wall 
were stained with hematoxylin and eosin to visualize general histology. Masson’s 
trichrome staining was used to distinguish cardiomyocytes and collagenous scar. 
4.3.4.2 Immunohistochemical stainings of CD31, αvβ3 integrin and α-SMA 
Samples from the non-viable area, immediately adjacent viable area, and from the 
remote area were stained with antibodies against αvβ3 integrin (dilution 1:200, 
Millipore, Temecula, CA, USA), CD31 to visualize endothelial cells and 
angiogenesis (dilution 1:250, Thermo Scientific, Cheshire, UK) and αSMA to 
visualize myofibroblast differentiation (dilution 1:30 000, Sigma-Aldrich, St. Louis, 
MO, USA). 
4.4 In vitro experiments 
4.4.1 Plasma protein binding (II) 
Binding of [68Ga]NODAGA-RGD to human, pig and rat plasma proteins was 
measured using an in vitro assay as described previously (Tarkia et al., 2012). 
4.4.2 Angiogenesis tissue model (III) 
Human cell-based 3D-model of angiogenesis was obtained from FICAM, Finnish 
Centre of Alternative Methods. Human adipose stromal cells (hASC) and human 
umbilical vein endothelial cells (HUVEC) were co-cultured on plastic coverslips 
placed in 24-well plate for receptor binding studies, or on chamber microscope slides 
for autoradiography studies. The tubule network formation was stimulated with 
growth factors VEGF and FGF-ß. Four different growth factor concentrations were 
used to obtain gradient in tubule network density. The maximal inductive 
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concentrations were 10 ng/ml VEGF and 1 ng/ml FGF-ß, which were reduced 25%, 
50%, and 75%. Co-culture of hASC and HUVEC cells without induction of tubule 
network using growth factors was used as a control. 
The use of the human fat tissue/umbilical cords was permitted by Local Ethics 
Committee in accordance with International Conference on Harmonisation (ICH) 
GCP guidelines (CPMP/ICH/135/95) and the World Medical Association 
Declaration of Helsinki (1964) and subsequent amendments. 
4.4.3 In vitro receptor binding (III) 
[68Ga]NODAGA-RGD was added on 24-well plates and incubated for 90 minutes at 
37°C. After dip-washing with PBS, the cover slips containing the vessels were 
removed from the wells and measured for radioactivity using gamma counter 
(Wizard 3”; PerkinElmer/Wallac, Turku, Finland).   
4.4.4 In vitro autoradiography (III) 
For the autoradiography, [68Ga]NODAGA-RGD was added on the  chamber 
microscope slides and incubated 90 min at 37°C. The tracer was removed, the 
chamber walls were removed, and cells were dip-washed twice with PBS. The slides 
were air dried for 10 minutes and exposed on a phosphor imaging plate (BAS-
TR2025, Fuji Photo Film Co. Ltd., Tokyo, Japan) for 1 h. The distribution of 
radioactivity on the plate was visualized and quantified using a Fluorescent Image 
Analyzer (Fujifilm FLA-5100, Fuji Photo Film Co. Ltd., Tokyo, Japan).  
4.4.5 Immunohistochemical stainings (III) 
After the measurements with gamma counter or autoradiography, the tissues were 
fixed in 70% ethanol for 15 min and stained with antibodies against von Willebrand 
factor (vWF) and collagen IV. The stained glasses were imaged, and the density of 
angiogenesis was visually evaluated and graded from 0 to 5. 
4.5 Statistical analysis 
All data are expressed as mean ± SD. Statistical analysis was done with SPSS 
Statistics software v. 21 and v. 25 (IBM, NY, USA). In study I, receiver operating 
characteristic (ROC) analyses were performed, Youden index was used to obtain 
optimal cut- off values for [15O]water PET in comparison to TTC staining and the 
method of DeLong was used to compare area under the curve (AUC) values (DeLong 
et al., 1988). A paired Student’s t test was applied for the comparisons of the 
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[68Ga]NODAGA-RGD uptake between ischaemic and remote areas. Comparisons of 
viable ischaemic, injured ischaemic and remote areas were done using ANOVA with 
Dunnett’s correction for remote group. Comparisons of different vessel densities 
were done using ANOVA with Bonferroni correction. A Pearson’s rank test (r) was 
used to analyse correlation between ex vivo autoradiography and αvβ3 integrin 
immunohistochemistry and Spearman’s rank test was used to analyse correlation 
between in vitro autoradiography and angiogenesis vessel density. p values less than 
0.05 were considered statistically significant.
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5 Results 
5.1 Imaging of myocardial blood flow and viability 
(I) 
5.1.1 MBF and PTF in MI 
According to circumferential profile analysis, transmural infarction showed lower 
absolute MBF, relative MBF and PTF than remote myocardium (0.45 ± 0.34 vs. 1.23 
± 0.47, p < 0.001; 0.37 ± 0.23 vs. 0.99 ± 0.014, p < 0.001; and 0.55 ± 0.12 vs. 0.84 
± 0.11, p < 0.001, respectively). Segmental absolute MBF, relative MBF and PTF 
by [15O]water PET decreased with increasing infarct volume fraction defined by 
TTC.  
When the thickness of the ROI was increased, the PTF values decreased. The 
difference between small and large ROI thickness was 12% ± 6% (p < 0.001) in 
segments with infarct volume fraction of < 75%, and 13% ± 10% (p = 0.29) in 
segments with transmural infarction. The ROI thickness had no effect on absolute or 
relative MBF. 
5.1.2 Detection of infarction 
ROC analysis of segmental relative MBF and PTF by [15O]water PET showed that 
relative MBF was more accurate than PTF in detecting any MI (segments with any 
infarction vs. no infarction) (AUC 0.76 vs. 0.68, p = 0.04). Relative MBF of ≤ 85% 
and PTF of ≤ 70% were the optimal cut-off values for the detection of any MI. These 
cut-off values demonstrated modest sensitivity, but high specificity and positive 
predictive value (Table 4). 
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Table 4  Performance of segmental relative myocardial blood flow (Rel MBF) and perfusable 
tissue fraction (PTF) by [15O]water PET in the detection of myocardial infarction. 
No infarction vs. any infarction 
 Sensitivity Specificity Positive 
predictive 
value 
Negative 
predictive 
value 
Accuracy 
Rel MBF (cut off ≤ 85%) 61% 84% 80% 67% 72% 
PTF (cut off ≤ 70%) 54% 79% 76% 61% 66% 
 
Relative MBF performed better than PTF (AUC 0.71 vs. 0.57, p = 0.004) in the 
detection of subendocardial infarction (segments with infarct volume fraction 1%-
49% vs. no infarction). There was no difference, however, between relative MBF 
and PTF in the detection of non-viable tissue defined as infarct volume fraction ≥ 
75% (AUC 0.90 vs. 0.89, p = 0.89). 
The average size of the transmural MI was 29% ± 15% of the LV measured by 
relative MBF and 29% ± 22% of the LV measured by PTF (p = 0.99) with the cut-
off values derived from the ROC curve analysis. 
5.1.3 Assessment of viability 
The recovery of function with the infarct volume fraction of 50-75% is not distinct 
and, therefore, two definitions of viability were tested. When the segments with 
infarct volume fraction of < 50% were defined as viable and segments with infarct 
volume fraction of ≥ 50% as non-viable, the ROC analysis showed AUC of 0.81 with 
relative MBF and 0.81 with PTF for the detection of viability (p = 0.97) (Figure 4. 
A). The optimal cut-off values for relative MBF and PTF were ≥ 79% and ≥ 66%, 
respectively. These cut-off values showed similar sensitivities, specificities, and 
diagnostic accuracies for the detection of viability (Table 5). Segmental relative 
MBF and PTF were also compared with PTI for the detection of viability in a subset 
of pigs. The ROC analysis showed AUC of 0.81 with PTI and there was no difference 
between PTI and relative MBF (p = 0.41) or PTF (p = 0.79). 
When the segments with infarct volume fraction of < 75% were defined viable 
and segment with infarct volume fraction of ≥ 75% as non-viable, AUC of 0.85 with 
relative MBF and 0.86 with PTF (p = 0.77) were found (Figure 4. B). The optimal 
cut-off values of ≥ 67% for relative MBF and ≥ 66% for PTF resulted in accuracies 
of 90% and 81%, respectively (Table 5). Comparison to PTI (AUC 0.9) showed no 
difference between PTI and relative MBF (p = 0.67) or PTF (p = 0.50). The optimal 
cut-off value of ≥ 82% of PTI yielded slightly better sensitivity, specificity, and 
diagnostic accuracy than those of relative MBF or PTF.  
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Figure 4.  Receiver operating characteristics (ROC) curve analysis of relative myocardial blood 
flow (Rel MBF) and perfusable tissue fraction (PTF) by [15O]water in the detection of 
myocardial viability with infarct volume fraction of < 50% (A) and with infarct volume 
fraction of < 75% (B). From original publication I. 
Table 4.  Performance of segmental relative myocardial blood flow (Rel MBF) and perfusable 
tissue fraction (PTF) by [15O]water in the assessment of myocardial viability. 
Viable tissue (infarct volume fraction < 50%) 
 Sensitivity Specificity Positive 
predictive 
value 
Negative 
predictive 
value 
Accuracy 
Rel MBF (cut off ≥ 79%) 81% 69% 92% 46% 79% 
PTF (cut off ≥ 66%) 82% 71% 92% 48% 80% 
PTF (cut off ≥ 70%) 74% 76% 93% 41% 74% 
 
Viable tissue (infarct volume fraction < 75%) 
Rel MBF (cut off ≥ 67%) 92% 73% 96% 59% 90% 
PTF (cut off ≥ 66%) 80% 83% 97% 39% 81% 
PTF (cut off ≥ 70%) 72% 88% 97% 32% 74% 
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5.2 Imaging of myocardial injury and angiogenesis 
(II and III) 
5.2.1 [68Ga]NODAGA-RGD in vivo PET 
The tracer activity in the blood pool remained higher than in the myocardium 
throughout the imaging session. Plasma protein binding study showed that the 
binding of [68Ga]NODAGA-RGD in the plasma proteins was low in all tested 
species. Plasma free fraction was 0.94 ± 0.011 in the rat, 0.93 ± 0.017 in the pig and 
0.91 ± 0.081 in the human serum. There was virtually no [68Ga]NODAGA-RGD 
uptake in the remote LV myocardium, whereas the uptake was regionally increased 
in in the ischaemic area in all pigs (Figure 5). The average myocardial 
[68Ga]NODAGA-RGD uptake was higher in the ischaemic area than in the remote 
myocardium (SUV 0.61 ± 0.12 vs. 0.49 ± 0.12, p=0.003). 
 
Figure 5. Representative polar maps of MBF measured by [15O]water PET at rest and during 
adenosine stress and uptake of [68Ga]NODAGA‑RGD. Increased [68Ga]NODAGA‑RGD 
uptake is co‑localised with an area of reduced myocardial perfusion (asterisks) as 
compared with the remote area (arrowhead). From original publication II. 
5.2.2 Histology 
Injured myocardium presented characteristic histological features of recent 
ischaemic myocardial injury including loose connective tissue with some mature 
collagen fibres. Myofibroblasts and inflammatory cells were abundant. In the viable 
ischaemic areas, the organisation of myocytes and connective tissue were normal, 
but some myocyte vacuolisation was seen. The immunohistochemical staining of 
CD31 showed no difference in the endothelial cell staining between remote, viable 
ischaemic and injured myocardium. The immunohistochemical staining of αvβ3 
integrin showed localised staining around the capillaries in the viable myocardium. 
The staining was diffuse in the injured myocardium and significantly higher, as 
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measured by areal percentage, than in the remote myocardium (23 ± 1.9% vs. 7.5 ± 
1.0%, p < 0.001). There was no difference between viable ischaemic myocardium 
and remote myocardium (10 ± 4.0% vs. 7.5 ± 1.0%, p = 0.15). The α-SMA staining 
was intense and, as measured by areal percentage, significantly higher in the injured 
myocardium than in the remote myocardium (7.2 ± 2.9% vs. 1.3 ± 0.75%, p = 0.019). 
5.2.3 Ex vivo experiments 
5.2.3.1 Biodistribution 
The uptake of [68Ga]NODAGA-RGD was higher in the injured (TTC negative) 
myocardium in comparison to the remote myocardium (SUV 0.79 ± 0.21 vs. 0.49 ± 
0.21, p = 0.016) . There was, however, no difference between the viable ischaemic 
(TTC positive) and remote myocardium (SUV 0.49 ± 0.17 vs. 0.49 ± 0.21, p = 0.99). 
5.2.3.2 Autoradiography 
Autoradiographs showed significantly higher [68Ga]NODAGA-RGD uptake in the 
injured than in the remote myocardium (4.6 ± 2.1 vs. 1.8 ± 0.61 PSL/mm2, p = 0.006). 
The uptake in the viable ischaemic myocardium was similar than in the remote 
myocardium (2.2 ± 0.85, p = 0.82). The [68Ga]NODAGA-RGD measured by 
autoradiography positively correlated to the area percentage of αvβ3 integrin staining 
in the tissue sections (rPearson = 0.73, p = 0.0013). 
5.2.4 In vitro experiments 
5.2.4.1 In vitro tracer binding 
The tracer binding study was performed for human cell derived angiogenesis tissue 
model with four different concentration of angiogenesis promoting growth factors. The 
tracer uptake measured by gamma counter gradually increased with increasing density 
of angiogenesis (Figure 6A-D). When compared to the control cells that were not 
treated with growth factors, the uptake of [68Ga]NODAGA-RGD was 1.6-fold higher 
with 25% growth factor concentration, 2.1-fold higher with 50%, 2.4-fold higher with 
75% and 2.5-fold higher with 100% growth factor concentration. In comparison to the 
growth factor concentration of 25%, the uptake of [68Ga]NODAGA-RGD was 
significantly higher with the 75% and 100% growth factor concentrations (Figure 6E). 
The [68Ga]NODAGA-RGD uptake correlated with the amount of angiogenesis 
visually evaluated from histological stainings (Figure 6F). 
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Figure 6. Representative images of the tubule networks with different growth factor 
concentrations: 25% (A), 50% (B), 75% (C) and 100% (D) stained with von Willebrand 
factor (red) and collagen IV (green) antibodies. The graph in E shows the vessel-to-
base cell layer ratio of [68Ga]NODAGA-RGD uptake with different growth factor 
concentrations, and graph in F shows the correlation between the vessel density and 
the  vessel-to-base cell layer ratio of [68Ga]NODAGA-RGD uptake. From original 
publication III. 
5.2.4.2 Autoradiography 
Autoradiography was performed to vessels with growth factor concentrations of 75% 
and 100%. The uptake of [68Ga]NODAGA-RGD was localized in the areas of 
angiogenesis and was significantly higher with 100% growth factor concentration in 
comparison to 75% growth factor concentration (vessel-to-base cell layer ratio 3.3 ± 
0.09 vs. 2.5 ± 0.63, p = 0.009) 
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6 Discussion 
6.1 Pig models of myocardial ischaemia and 
infarction 
Pigs with a surgically or percutaneously induced myocardial ischaemia and 
infarction were used in this study. Pigs are well suited for translational 
cardiovascular research since they offer several advantages in comparison to other 
animal models. Pigs are almost identical to humans in relation to the heart and 
coronary artery blood supply. The heart weight-to-body weight ratio of pigs is 
comparable to that of humans enabling the use of clinical scanners and more reliable 
discrimination between the injured and normal myocardial areas. (Lelovas et al., 
2014; Swindle et al., 2012) 
The surgical model is relatively laborious to perform and uncomfortable for the 
animals but results in quite large MI (Tarkia et al., 2015; Teramoto et al., 2011). 
Stent implantation has been shown to immediately cause severe reduction in blood 
flow in the target coronary artery (Rissanen et al., 2013).  The occlusion of the stent 
can be mediated by antiplatelet medication, which was continued throughout our 
studies. Despite the medication, injured myocardium was found in some of the 
stented pigs probably due to insufficient compensation for reduction in myocardial 
perfusion by collateral formation, occlusion of a side branch by the stent, or 
thrombosis within the stent. 
The pigs used in our studies were three months old in the beginning of the 
studies. The CAD patients, however, are usually older and might have comorbidities 
limiting their capability to adapt to the ischaemia. Use of older pigs is not as feasible 
due to their growth rate, which can be avoided to some extent by using minipigs. 
Another limitation for using pigs is challenges in the handling of the animals due to 
their size and higher costs of the housing of the animals, especially if older, larger 
animals and long follow-up times are used. 
Regarding the medications used in our studies, there are some limitations that 
should be acknowledged. We used propofol in maintaining the anaesthesia. Propofol 
is a vasorelaxant leading to a decrease in vascular resistance and arterial pressure 
without affecting the heart rate. It also might pose a challenge regarding interactions 
with stress agents used in perfusion studies. (Croteau et al., 2004). We used 
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adenosine as a pharmacologic stress agent. Pigs often have variable systemic 
haemodynamic responses to adenosine and the dose had to be adjusted in some pigs. 
Adenosine infusion was combined with α1-adrenoceptor agonist phenylephrine, 
which can be used to counteract the systemic effects of adenosine leaving the 
adenosine-induced coronary vasodilatation undisturbed (Rossi et al., 2013). 
Dipyridamole has been shown to provide stronger hyperemic response than 
adenosine in the heart of propofol-anaesthetised pig (Rasmussen et al., 2016b). 
6.2 Imaging of myocardial blood flow and viability 
Viable but dysfunctional myocardium has potential to regain contractile function 
after restoration of blood flow. Thus, the detection of viable myocardium, in addition 
to ischaemia, is clinically important in determining the patients with CAD who will 
most likely benefit from revascularisation. Several imaging techniques, such as 
echocardiography, MRI, SPECT, and PET, have been used to assess viable 
myocardium. Of these, [18F]FDG PET in combination with perfusion imaging is 
considered the most optimal technique. Also PTF and PTI by [15O]water PET have 
been shown to detect viability and predict functional recovery after MI (Bondarenko 
et al., 2011; Iida et al., 2012; Itoh et al., 2002; Timmer et al., 2017; Yamamoto et al., 
1992). The detection of viability with resting MBF assessed by [15O]water PET, 
however, still remains incompletely studied. We evaluated the performance of 
resting relative MBF, PTF an PTI by [15O]water PET in the detection of  MI and 
viability. Relative MBF, PTF and PTI were segmentally compared to histology.  
Due to its optimal characteristics, [15O]water PET is considered the golden 
standard for perfusion imaging. In clinical practise, assessment of ischaemia and MI 
is normally performed with combined rest and stress imaging. Reduced resting MBF 
is a marker of an MI scar both in experimental models (Bol et al., 1993; Herrero et 
al., 1995; Iida et al., 1995) and in patients (de Silva et al., 1992; Gerber et al., 1998; 
Iida et al., 2012). We showed an MBF of 0.45 ± 0.34 ml/g/min in the centre of 
transmural infarction which is in line with previous studies showing MBF values 
between 0.35 and 0.45 ml/g/min in necrotic areas (Bol et al., 1993; de Silva et al., 
1992; Herrero et al., 1995). There was a gradual decrease of segmental absolute and 
relative MBF and PTF with increasing infarct volume fraction. Also, absolute and 
relative MBF were decreased in segments with any infarction, but PTF was lower 
only when the infarct volume fraction was ≥ 50%.  
We also studied the effect of ROI thickness on the MBF and PTF. MBF is 
independent of ROI thickness (Iida et al., 1988) and, as expected, increasing the 
thickness of the ROI had no effect on absolute or relative MBF, whereas it resulted 
in a reduction of PTF. PTF is the fraction of tissue capable of rapidly exchanging 
[15O]water in a specific ROI. Increasing the thickness of the ROI decreases PTF 
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because more extramyocardial components are included in the ROI. As PTF is 
sensitive for variations, careful standardisation of ROI definition is required. PTI is 
the ratio of PTF and ATF which both decrease equally with increasing ROI 
thickness, and therefore, PTI will remain inaffected by changes in ROI thickness. 
(Knaapen et al., 2003) ATF is the mass of extravascular tissue in the ROI, and can 
be determined by blood-pool imaging with [15O]CO or a software-based calculation 
of parametric PTI images from single [15O]water scan (De Haan et al., 2012; Harms 
et al., 2011).  
For the detection of viability defined as segments with infarct volume fraction < 
75%, our study showed optimal cut-off values of ≥67% for relative MBF, ≥ 66% for 
PTF and ≥ 82% for PTI, which are in line with previous studies showing cut-off 
values of 70% for PTF and 85% for PTI (Bondarenko et al., 2011; De Haan et al., 
2012). Previous literature has shown, however, variation between 70 and 85% in the 
cut-off values for PTI (De Haan et al., 2012; de Silva et al., 1992; Timmer et al., 
2017). Although the cut-off value for the PTF determined by us was quite similar 
than previously reported, it resulted in lower diagnostic accuracy in our material. 
The ROC analysis showed AUC of 0.85, 0.86, and 0.90 for MBF, PTF, and PTI, 
respectively. Relative MBF showed high sensitivity for detecting viable segments, 
but the specificity was lower. This might be due to normal MBF in some areas of 
subendocardial infarction. 
Accuracy of 79-90% with relative MBF in the detection of viability shown by us 
is higher or similar than with [18F]FDG PET (79%), dobutamine echocardiography 
(79%), [99mTc]sestamibi SPECT (75%), [201Th] SPECT (71%), and MRI techniques 
(61%-78%) with the endpoint of improvement of regional function (Schinkel et al., 
2004). Combination of [18F]FDG and perfusion PET is considered the best method 
to assess viability. It requires, however, two PET scans leading to longer imaging 
sessions and higher radiation burden for the patients. With [15O]water PET, the 
perfusion and viability could be assessed with the same imaging session. The clinical 
endpoint in viability studies is recovery of contractile function after revascularization 
which, in addition to cut-off values, needs to be evaluated in future clinical studies 
with patients. Our experimental study, however, shows that evaluation of viability 
by [15O]water PET is feasible. 
We determined relative MBF by normalising the absolute MBF values for 
remote normal myocardium. The use of reference region and relative values, 
however, might be problematic in patients with multi-vessel disease and quantitative 
approach should be used. The cut-off values for relative rather than absolute MBF 
were, however, determined due to concerns related to species differences and effects 
of anesthesia. Also, large variability in the resting global flow can often been seen 
in pigs with MI scar.  
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6.3 Imaging of myocardial injury and angiogenesis 
The molecular processes taking place during infarct healing serve as potential 
biomarkers for the assessment of risk for developing LV remodelling and heart 
failure.  Expression of αvβ3 integrin is associated with several events during cardiac 
repair after myocardial infarction, including angiogenesis, regulation of macrophage 
inflammatory responses and myofibroblast differentiation (Antonov et al., 2011; 
Sarrazy et al., 2014; Sun et al., 2003). RGD-based αvβ3 integrin targeted tracers 
detect increased αvβ3 integrin expression after ischaemic myocardial injury in animal 
studies and in humans (Higuchi et al., 2008; Makowski et al., 2008; Meoli et al., 
2004; Rasmussen et al., 2016a; Sun et al., 2014), and have shown potential to predict 
LV remodelling (Sherif et al., 2012) and functional recovery after revascularisation 
(Jenkins et al., 2016). [68Ga]NODAGA-RGD is a novel PET tracer that consists of a 
pentacyclic peptide binding moiety Arg-Gly-Asp-D-Tyr-Lys coupled with the 
gallium chelating agent NODAGA. The tracer precursor is commercially available 
in Good Manufacturing Practices (GMP) quality and the tracer has been tested for 
clinical use (Gnesin et al., 2017; Van Der Gucht et al., 2016). The synthesis of 
[68Ga]NODAGA-RGD is relatively easy and straightforward, and it has a good target 
specificity and favorable kinetics, dosimetry and safety profile (Buchegger et al., 
2011; Knetsch et al., 2011).  
[68Ga]NODAGA-RGD uptake has been shown to demonstrate αvβ3 integrin 
expression in infarcted rat myocardium 1 week after coronary ligation (Laitinen et 
al., 2013), which is in line with our study showing that the [68Ga]NODAGA-RGD 
cardiac PET detected increased myocardial αvβ3 integrin expression two weeks after 
the induction of flow-limiting coronary stenosis in pigs. The uptake of 
[68Ga]NODAGA-RGD was localised in the injured myocardium, but not in the 
viable ischaemic myocardium indicating that [68Ga]NODAGA-RGD is a potential 
tool in detecting areas of recent myocardial injury in the presence of chronic 
ischaemia and in evaluating patients with hibernating myocardium containing a 
mixture of viable ischaemic and injured myocardium (Elsasser et al., 1997).  
The in vivo PET imaging showed an increased uptake of [68Ga]NODAGA-RGD 
in the ischaemic myocardium, but the ex vivo biodistribution and autoradiography 
showed that the uptake was localised in the irreversibly injured myocardium, but not 
in the viable myocardium within the ischaemic area. The immunohistochemical 
staining of αvβ3 integrin confirmed the increased expression, which also correlated 
with the [68Ga]NODAGA-RGD uptake measured by autoradiography. We found no 
difference in the endothelial cell staining between the remote, viable ischaemic and 
infarcted myocardial areas, but the staining of α-SMA showed myofibroblast 
differentiation in the infarcted areas. These results indicate that, instead of 
angiogenesis, the αvβ3 integrin expression and [68Ga]NODAGA-RGD uptake 
reflected other processes related to scar formation. It has been shown that αvβ3 
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integrins are, indeed, expressed on myofibroblasts (Hinz, 2006) and RGD tracer 
uptake after experimental MI  has also been traced to myofibroblasts (van den Borne 
et al., 2008). Angiogenesis and RGD tracer uptake have previously been shown to 
take place in severely hypoxic tissue (Dobrucki et al., 2009; Kalinowski et al., 2008). 
The severity and duration of ischaemia in our pig model, however, may not have 
been enough to induce angiogenesis. The αvβ3 integrin expression and RGD uptake 
peak between 1 and 4 weeks after an ischaemic insult (Higuchi et al., 2008; Kiugel 
et al., 2014; Meoli et al., 2004; Sun et al., 2003). We chose the time point of 2 weeks 
for our study according to this, and the lack of other time points is a limitation. 
Previously, a direct correlation between the amount of endothelial cell staining and 
uptake of dimeric [68Ga]DOTA-RGD tracer has been shown at 4 weeks after MI 
indicating increased angiogenesis in the later stages of scar formation (Kiugel et al., 
2014). Our study is, however, in line with a previous study in a pig model of 
myocardial hibernation where no angiogenesis or uptake of RGD was found 
(Johnson et al., 2008).  
Since the expression of αvβ3 integrin and uptake of RGD tracers also reflect other 
processes than angiogenesis in infarcted myocardium, we studied the 
[68Ga]NODAGA-RGD binding in an human cell based angiogenesis tissue model, 
which is devoid of most other RGD binding targets, such as macrophages. This in 
vitro study showed that the [68Ga]NODAGA-RGD binding is proportional to the 
amount of angiogenesis. However, when performing in vivo imaging studies of 
angiogenesis, possibility of nonspecific binding should be acknowledged. 
The vessels in the tissue model have previously been shown to be covered by 
pericytes (Huttala et al., 2015; Sarkanen et al., 2011; Toimela et al., 2017). Pericyte 
coverage is characteristic to maturation of newly formed vessels in myocardium after 
infarction (Kobayashi et al., 2017) indicating that the model used here represents 
well the post-infarction angiogenesis. The αvβ3 integrin also seems to be involved in 
the maturation of the vessels as anti-αvβ3 integrin therapy has been shown to decrease 
pericyte coverage in tumor vessels (Reinmuth et al., 2003).  
One of the limitations in this study is the fact that the effect of therapeutic 
angiogenesis on [68Ga]NODAGA-RGD uptake was not tested. The possibility to 
monitor the response to angiogenic gene therapy with targeted PET tracers is 
intriguing. Previously, RGD-based tracers [123I]Gluco-RGD and [18F]alfatide II 
([18F]AlF-NOTA-E[PEG4-c(RGDfk)]2) have been shown to detect gene therapy 
induced angiogenesis in hibernating pig myocardium (Johnson et al., 2008) and in 
rats after MI (Cai et al., 2016), respectively. 
For logistic reasons, two different PET/CT scanners for [15O]water and 
[68Ga]NODAGA-RGD imaging were used. This might have affected the accuracy of 
the co-registration of the images. Also, respiratory and cardiac motion may affect 
sensitivity of [68Ga]NODAGA-RGD due to activity in the closely associated blood 
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pool in which the tracer uptake remained higher than the myocardial uptake 
throughout the imaging session. No clear explanation for the persistent high blood 
uptake in our pig model was found. There were no species differences in the binding 
of the tracer to plasma proteins between pigs, rats, and humans. Low amounts of αvβ3 
integrin, however, can be found on platelets (Bennett et al., 2009). Platelet count in 
pigs is much higher than that of humans (Chen et al., 2011) resulting in higher 
amount of αvβ3 integrin in blood and possibly explaining the higher blood 
radioactivity in pigs than in human. 
6.4 Future directions 
Molecular imaging with PET is a valuable tool in the discovery and initial evaluation 
of new therapies and in the diagnostics and risk stratification of patients. PET 
imaging of biological processes involved in the healing of MI and LV remodelling 
could be used as prognostic markers in identifying patients at high risk for 
developing HF, and in the evaluation of the efficacy of new therapies (Saraste & 
Knuuti, 2017).  
[15O]water PET is well established for the detection of CAD (Driessen et al., 
2017). Our results show that [15O]water PET is a potential tool in the detection of 
viability. This was, however, an animal study and the cut-off values need to be 
determined in patients. Functional recovery after revascularisation is most used 
clinical end point in viability studies (Schinkel et al., 2007), and should be evaluated 
in future clinical studies of viability assessment using [15O]water PET. Also, direct 
comparison of [15O]water PET with some other techniques or tracers, such as 
[18F]FGD for viability assessment would be of interest.  
Different characteristics during infarct healing and LV remodelling serve as 
potential biomarkers for the detection and risk stratification of HF. Several new 
tracers for the detection of angiogenesis after MI to predict LV remodelling and 
development of HF have been studied, also in patients (Jenkins et al., 2016), but none 
are yet in routine clinical use. The prognosis of HF is poor as half of the patients 
with HF die in five years (Mcmurray & Pfeffer, 2004). Thus, new, and more effective 
therapies, such as angiogenic gene therapy are needed for the treatment of these 
patients. Monitoring of the therapy response to angiogenic gene therapy has, so far, 
been done for example with perfusion imaging (Hartikainen et al., 2017). It would, 
however, be of interest to directly detect the amount of neoangiogenesis in the 
treatment area. RGD based tracers, such as [68Ga]NODAGA-RGD are potential tools 
for this purpose. The tracer already has been studied in humans with cancer (Van 
Der Gucht et al., 2016) and carotid artery disease (Gnesin et al., 2017), and studies 
with MI patients are ongoing. Our results showed that RGD uptake correlated with 
the amount of angiogenesis in vitro, but more studies are still needed to determine to 
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which extent the in vivo uptake of RGD based tracers is from angiogenesis and to 
which extent from other possible targets with increased αvβ3 integrin expression, 
such as myofibroblasts and macrophages. 
 
 56
7 Conclusions 
This study evaluated PET tracers for the detection of myocardial viability and repair 
process after MI. The main findings and conclusions of the studies I-III are 
following:  
1. Resting MBF, PTF, and PTI based on [15O]water PET perfusion imaging 
detected myocardial viability with good accuracy. 
2. [68Ga]NODAGA-RGD PET demonstrated increased myocardial αvβ3 
integrin expression in a pig model of coronary stenosis. The uptake of 
[68Ga]NODAGA-RGD was localised in the irreversibly injured 
myocardium. 
3. [68Ga]NODAGA-RGD binding was proportional to the amount of 
angiogenesis in an in vitro 3D model of angiogenesis. 
Resting MBF, PTF and PTI based on [15O]water PET perfusion imaging are useful 
for the assessment of myocardial viability. [68Ga]NODAGA-RGD PET may be 
useful for the identification of αvβ3 integrin activation associated with repair of 
myocardial injury. 
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